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DESIGN AND EVALUATION OF SELECTIVE ANTICANCER DRUGS AND
TREATMENT SCHEDULES
K. R. HARRAP
From the Department of Biochemical Pharmacology, Institute of Cancer Research, Belmont,
Sutton, Surrey, England
MEMBERS OF the present generation of
clinically used anticancer drugs are pre-
dominantly cytotoxic chemicals which exhibit
little selectivity for tumour cells. There is
an unequivocal need to discover and develop
more selective compounds.
An essential requirement for selective drug
design is the identification of a biochemical
abnormality unique to the target tissue which
might provide a focus for chemical attack.
The most consistent qualitative abnormality
reported in tumours is their aberrant regula-
tion of gene expression, both transcriptional
and translational processes being affected.
These events are generally accompanied by
only quantitative changes in intermediary
metabolism; therapeutically exploitable en-
zyme defects appear to be rare, though not
unique (Harrap, 1975, 1979). The altered
transcriptional patternoftumourcellsappears
to derive from structural and functional
changes in the regulatory non-histone chrom-
osomal proteins (Stein et al., 1978). How-
ever, it is unquestionably premature to
contemplate the design of agents which
might selectively modulate these processes.
Much work will first be required to isolate
and characterize these proteins and to identify
theirregulatory functions. Ontheotherhand,
good progress has occurred in the design of
small-molecule inhibitors capable of influen-
cing the outcome of translational events.
Notably it has been shown that S-adenosyl
homocysteine is a strong competitive inhib-
itor of t-RNA methyltransferase activity,
while some of its analogues exhibit selective
avidities for individual enzymes (Trewyn &
Kerr, 1976; Kogan et al., 1976; Legraverend
etal., 1977).
Our own approach to the design of new
agents has relied on identifying enzymes
critical to the tumour, which are also amen-
able to selective chemical attack. In addition
we have attempted to develop less toxic
congeners ofestablished drugs. We have also
given some attention to the design of "host-
protective" protocols incorporating drugs
currently in clinical use. This programme
will be elaborated under the following head-
ings.
Development of techniques designed to enhance
the efficacy of established drugs
In view of the poor performance of drugs
currently in clinical use and the extensive
delays involved in the introduction and
acceptance of new agents into the clinic,
there is a pressing need to improve the utility
ofthe present generation ofanticancer drugs.
Accordingly we have devised techniques,
based on the biochemical properties of
individual drugs, which are protective in
relation to host toxicity while also enhancing
tumour-cell kill. Particular attention has
been devoted to the alkylating agents and to
methotrexate (MTX).
In the former case we have been able to
show that the systemic toxicity of chlor-
ambucil can be substantially reduced by the
delayed administration ofprednisolone, while
the antitumour efficacy of the alkylating
agent is considerably enhanced (Harrap et al.,
1977a). This has led to the successful replace-
ment of mustine with chlorambucil in the
MOPP schedule (McElwain et al., 1977).
Prednisolone appears to potentiate the
cytotoxicity of several alkylating agents, this
effect being associated with changes in
nuclear protein structure and function
(Riches & Harrap, 1973; Harrap et al., 1975;
Wilkinson & Harrap, 1973; Riches et al.,
1977). The improved therapeutic index
of chlorambucil/prednisolone combinations
appears to relate to steroid-enhanced binding
of chlorambucil to tumour nuclear proteins,
with concomitant suppression of binding to
nuclear proteins from gut mucosal cells
(Harrap et al., 1980c; Wilkinson et al., 1979).
The systemic toxicity incumbent on the
use ofMTX at high doses is routinely averted
by the delayed administration of folinic acid.
However, this technique also reduces the
tumoricidal effects of the drug. We have
found that it is possible to sustain the effects
of the drug against tumour cells, while
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protecting susceptible host tissues from toxi-
city, by selective reversal of the drug's
effects with combinations of purine and
pyrimidine nucleosides (Harrap et al., 1977b).
The effects appear to depend on differences
in purine/pyrimidine anabolism and cata-
bolism in tumour and host tissues. It is also
possible to reverse the systemic toxicity of
MTX in man by a similar technique, though
the ultimate clinical utility of the method
awaits further evaluation (Dady et al., 1980).
Enzyme-targeteddrugs
In addition to the serendipitous discovery
of qualitative enzyme defects in tumours, it
is also possible to identify individual enzymes
as potential targets for chemotherapy, based
either on the importance of the enzyme to
tumour proliferation per se, or on a knowledge
of the molecular basis for treatment failure
with a given agent. Examples will be quoted
from three studies.
Adenosine deaminase (ADA).-Activity is
extensively raised in T-cell acute leukaemias
(Smyth & Harrap, 1975). The enzyme is
apparently essential for lymphoid function,
its genetic deletion being associated with the
severe combined-immunodeficiency disease
of childhood. The availability of deoxyco-
formycin, a tight-binding inhibitor of ADA,
permitted us to explore the possible thera-
peutic utility of ADA inhibition. The anti-
tumour efficacy of the inhibitor appears to
derive from the generation of enhanced
intracellular levels of dATP and associated
inhibition of ribonucleotide reductase (Paine
et al., 1980a). In a Phase I clinical study the
compound appeared to be selectively lympho-
toxic, while some antitumour efficacy was
apparent in T-cell acute leukaemias. How-
ever, attempts to potentiate the effects of
deoxycoformycin in animals by concurrent
administration of deoxyadenosine produced
profound hepatotoxicity (Paine et al., 1980b).
Thymidine kinase.-The ability of tumour
cells to utilize (salvage) circulating pyrimi-
dines may enable them to circumvent a drug-
imposed blockade of de novo pyrimidine
biosynthesis. The availability of inhibitors
of thymidine kinase should permit the poten-
tiation of antipyrimidines. We have been
studying a series of mixed di- and tri-
phosphonates ofthymidine in relation to their
affinity for the TTP (negative effector) site
on the enzyme. One of these derivatives is
4 times as effective an inhibitor as TTP and
prevents cells from utilizing thymidine at
concentrations found in plasma.
Thymidylate synthetase (TS). MTX is a
tight-binding inhibitor of dihydrofolate re-
ductase (DHFR) and a weak inhibitor of TS.
Treatment failure is attributable either to
impaired membrane transport or to the
generation of high levels of DHFR. Under
the latter circumstance, inhibition of TS by
free intracellular MTX becomes qualitatively
more significant: in highly MTX-resistant
(enzyme) mutants the cytotoxic outcome of
MTX treatment is determined entirely by
inhibition of TS (which in any case is always
the rate-limiting enzyme determinant of de
novo thymidylate biosynthesis). A major
component of the gastrointestinal toxicity
induced by MTX may relate to its ability to
induce rapidly a purineless condition in the
gut (Straw et al., 1977; Harrap et al., 1977b)
which cannot result if TS is selectively inhib-
ited. For these reasons we have synthesized
a range of quinazoline analogues of folic acid
as potential inhibitors of TS. One of these, a
10-propargyl quinazoline, possesses a Ki of
10-9 M for the enzyme. It exhibits substan-
tially improved antitumouractivitycompared
with MTX in a number ofsystems, and is also
active against MTX-resistant cells (Jones,
1980; Calvert et al., 1980; Harrap et al.,
1980a; Jones et al., 1980).
Synthesis of "Second Generation Drugs"
It is possible to identify several clinically
established drugs which possess useful anti-
tumour properties, but whose intensive
utilization is prohibited by the onset ofsevere
dose-limiting toxic side effects. However,
quantitative structure-activity studies permit
the identification of congeners in which the
useful antitumour properties of the parent
compounds are preserved, with considerable
reduction in systemic toxicity. In this con-
nection our interest has been focused on the
identification of second-generation alterna-
tives to neoplatin (cisPtll), hexamethyl-
melamine (HMM) and DTIC (5-(3,3-dimethyl-
triazeno)imidazole-4-carboxamide).
Our evaluation of alternative platinum
complexes has permitted the selection of
cis-diammine-1.1-cyclobutane dicarboxylate-
PtIl as a viable candidate for early clinical
trial. This compound is apparently not
nephrotoxic, and is also less emetic than
neoplatin. It also exlhibits a wider spectrum
of antitumour activity than the parent com-
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pound (Harrap et al., 1980b). Studies with
alternatives to H1MM have led to the identi-
fication and clinical trial of a more water-
soluble analogue, pentamethylmelamine,
which can be administered systemically at
well tolerated doses to provide circulating
melamine levels about 20 x those which can
be obtained from a maximum tolerated dose
ofthe parent compound (which must bo given
orally) (Smith et al., 1980). Studies with
DTIC analogues have shown that replacing
the imidazole by an aromatic carrying struc-
ture yields a series of photostable derivatives
possessing enhanced therapeutic indices
against experimental tumours (Wilman &
Goddard, 1980).
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PRETREATMENT WITH CERTAIN CYTOTOXIC DRUGS REDUCES THE
NORMAL TISSUE TOXICITY OF ANTI-CANCER AGENTS IN MICE AND MAN
J. L. MILLAR*, I. E. SMITHt, AND T. J. McELWAINt
* From the Institute of Cancer Research and tRoyal Marsden Hospital, Sutton, Surrey, England
SEVERAL YEARS ago Smith and her col-
leagues noticed that pretreatment with
certain stathmokinetic agents (namely vin-
blastine, vincristine or colchicine) two days
before total-body irradiation reduced the
marrow toxicity of the radiation in mice
(Smith et al., 1968; Brecher et al., 1967).
Independently Jeney and co-workers, using
rats, established that pretreatment with low-
dose merophan or melphalan protected
animals from an otherwise lethal dose of
merophan or melphalan respectively (Jeney
et al., 1968). Neither of these two research
groups examined the effect of these normal
tissue-sparing combinations on malignant
tissue.
More recently these studies have been
extended to show that a wide variety ofcyto-
toxic agents, when used at appropriate low
doses will protect against radiation or drug-
induced marrow lethality. These agents
include cyclophosphamide (cy), cytosine
arabinoside, methotrexate and chlorambucil
Millar et al., 1975, 1978a.
The marrow is not the only mouse normal
tissue that can be spared by drug pretreat-
ment. Studies involving the administration
ofcy showed that pretreatment with low-dose
cy 4 days before high-dose cy reduced the
damage caused by the high dose of cy to the
urothelium and improved animal survival
Millar & McElwain, 1978). Further, toxicity706 BACR AND RSM JOINT MEETING
to intestinal epithelium caused by high-dose
melphalan can be reduced by pretreatment
2 days before with low-dose cy, cytosine
arabinoside or melphalan itself (Millar et al.,
1978b). Radiation given at high enough
doses also critically damages this tissue, and
it has been shown that cytosine arabinoside
given 12 h before irradiation reduces the
damage to the gut (Phelps & Blackett, 1978).
It is likely that cell synchrony plays a part
in the protection phenomenon in this
instance.
Althoughtheinvestigations ofthesenormal-
tissue-sparing combinations on tumours have
not been extensive, the results so far have
suggested that tumour tissue may not be
similarly spared. Using the normal-tissue-
sparing combination of 50 mg/kg cy 4 days
before high-dose cy (250-350 mg/kg) in a
curability experiment involving the Lewis
lung carcinoma, it was established that this
sequency of drug administration maintained
its expected anti-tumour efficacy (Millar &
McElwain, 1978). Further, in studies invol-
ving drug-induced growth delay of the FS6
fibrosarcoma, it was established that the
pretreatment dose could be escalated without
reversing the normal-tissue-sparing proper-
ties of the sequence, yet improving the anti-
tumour effect (Millar et al., 1980).
In experiments involving the marrow-
sparing combination of cytosine arabinoside
2 days before irradiation, growth-delay
studies with the Lewis lung tumour indicated
that pretreatment with cytosine arabinoside
neither protected tumour cells nor enhanced
regrowth of tumour cells that survived the
irradiation (T. Stephens and J. Peacock,
personal communication) again suggesting
that malignant tissue does not respond in the
favourable way in which marrow or intestinal
epithelium respond to this combination.
Although several hypotheses have been put
forward to explain this selective protection
of normal tissue, they have all been dis-
proved and the phenomenon still awaits
convincing explanation.
In the meantime, steps have been taken to
investigate the phenomenon in larger mam-
mals and, as a first step, sheep were used and
the effect of high-dose melphalan on sheep
intestinal epithelium with and without cy
pretreatment was investigated. It was estab-
lished that pretreatment with cy reduced the
toxicity of melphalan to the intestinal
epithelium when given 5-9 days before the
dose of melphalan (Millar et al., 1978c). This
indicated that the time interval between pre-
treatment and challenge was longer for large
mammals, and an interval of 7 days was
used in studying human tissue response.
Human tumours have been grown in
immune-deprived mice for some time in this
laboratory (Steel et al., 1978). Human
melanoma xenografts were used in a growth-
delay study to establish whether a normal-
tissue-sparing combination of cy and mel-
phalan reduced the efficacy of the drugs
against melanoma. No such alteration in
efficacy was seen, suggesting that, once again,
combinations of drugs which spare normal
tissue do not spare tumour tissue.
The study of the combination of cy 7 days
before high-dose melphalan in the treatment
of disseminated malignant melanoma in man
was instigated. Previously, doses of mel-
phalan ranging from 60 to 120 mg/M2 had
been used in single-agent studies, and a
pattern of marrow suppression reflected in
leukopenia had been established. A pre-
treatment dose of 300 mg/M2 cy was given
7 days before 140 mg/M2 melphalan and it
was noticed that the peripheral leucocytes
recovered slightly more rapidly in these
patients than in the group that were not
pretreated (Hedley et al., 1978). The clinical
response of the tumour appeared to be
unaltered by the cy pretreatment.
In conclusion, there are combinations of
cytotoxic agents which spare normal tissue
such as marrow, intestinal epithelium and
urothelium. This phenomenon has been
observed in mice, rats, sheep and man. In
all experimental tumour systems tested so
far these normal-tissue-sparing combina-
tions appear to maintain their anti-tumour
efficacy, thus improving the therapeutic
index.
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THERAPY OF GASTROINTESTINAL CANCER
J. S. MACDONALD
From the National Cancer Institute, U.S.A.
THE TREATMENT of adenocarcinoma of the
stomach, pancreas and colon has generally
been surgical in the past. However, recent
clinical trials have suggested that chemo-
therapy and combined chemotherapeutic
and radiation therapy programmes may be
making major gains in both the adjuvant
treatment of these diseases and in the treat-
ment of advanced unresectable cancers. In
the management of locally unresected gastric
cancers, a study recently reported by the
Gastrointestinal TumourStudyGroup (Schien
& Novak, 1980) has shown that the com-
bination of 50 Gy of split-course irradiation
followed by 5 FU plus Methyl CCNU com-
bination chemotherapy is superior to 5-FU
plus MeCCNU alone. In this two-armed
randomized trial in which 45 patients were
treated with chemotherapy and 45 with
chemotherapy plus radiation, it was shown
that although the median survival was better
for the chemotherapy alone patients, (18
months vs 9 months) the long-term survival
was better for patients treated with the
combined modality. Eight of 45 patients
(18%) in the combined-modality arm were
alive and free ofdisease at more than 31 years
after diagnosis. In the chemotherapy-alone
arm only 3/45 patients (7%) survived. The
nearly 20%/ survival of patients with docu-
mented unresectable gastric cancer suggests
that combined-modality therapy with local
radiation followed by systemic chemotherapy
should be used as a standard arm to which
new therapies should be compared in future
studies of locally unresectable gastric cancer.
In patients with advanced gastric cancer,
major advances have been made through the
use of combination chemotherapy (Mac-
donald et al., 1979). The FAM (5-fluorouracil,
Adriamycin and mitomycin-C) chemotherapy
regimen, designed by investigators at the
Vincent T. Lombardi Cancer Research Center
at Georgetown University, has shown par-
ticularly promising results in advanced
gastric-cancer patients. In a series of 62
patients with advanced measurable malig-
nancy, 26 partial responses were noted. This
42% response has been confirmed in studies
from the University of Chicago (Bitran et al.,
1979). and Southwest Oncology Group
(Panettiere & Heilbrun, 1976). The median
duration ofresponse in the Georgetown study
was 9 months, and median survival in
responding patients was 12 months. These
responses and survival durations suggest that
the FAM regimen should be tested in pros-
pective trials as an adjuvant to surgery in
gastric cancer. Such studies are now under
way.
The medical management of pancreatic
cancer has been generally unsatisfactory,
though there is now evidence that the com-
bined use ofradiation therapy and 5-FU may
be superior to radiation alone in locally
unresectable patients (Lokich, 1979). A
study performed by the Gastrointestinal
Tumour Study Group in which patients with
unresectable pancreatic cancer wererandomly
allocated to receive either 60 Gy of split-
course radiation or 60 Gy plus 5-FU or
40 Gy of split course radiation plus 5-FU
showed that the combined modality arms of
radiation plus 5-FU were statistically super-
ior in prolonging survival to radiation therapy
alone. The median survival in the combined-
modality arms varied between 36 and 41
weeks whereas the median survival after
60 Gy radiation alone was 21 weeks. The
median survival in patients receiving no
therapy after documentation of unresectable
pancreatic cancer is about 12-16 weeks.
In patients with colorectal cancer, there
has been much interest in the use ofadjuvant
chemotherapy or combined-modality radia-
tion and chemotherapy. In the United States
over 100,000 new cases of colorectal cancer
occur per year, and the 5-year survival with
surgery alone is - 50%. In patients with
resected Dukes B or C colon cancer there
have been numerous adjuvant chemotherapy
studies (Moertel, 1976). These studies have
used single agents, combinations of agents
and occasionally combinations of chemo-
therapy and immunotherapy. Appropriately
designed studies of adjuvant therapy in
colon cancer must at present incorporate a
control arm treated with surgery alone, since
there has been no confirmation of the effec-
tiveness of any adjuvant therapy. The
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Gastrointestinal Tumour Study Group (un-
published) has recently completed a 4-arm
controlled study in which surgery alone is
compared to 5-FU plus MeCCNU chemo-
therapy, MER (methanol-extracted residue
of BCG) immunotherapy and chemoimmuno-
therapy with 5-FU MeCCNU and MER. The
study has over 550 patients, and at present
there appears to be no difference between any
of the treatment arms and the surgery alone
arm. It is important to note, however, that
in carefully staged and operated patients, as
demonstrated in this study, the survival of
patients with Dukes B2 disease is excellent
and is >75% at 2 years after surgery.
Because of the prevalence of local recur-
rence in patients with rectal cancer, studies
have concentrated on the use of radiation
therapy or radiation therapy plus chemo-
therapy as an adjuvant to surgery in these
patients. Although there have been sug-
gestions that both low dose (5-25 Gy) and
high-dose ( >40 Gy) preoperative therapy
are useful in preventing recurrence of rectal
cancer and prolonging survival, it is difficult
to find carefully controlled prospectively
randomized studies in which clear benefit is
statistically confirmed. Recently the Gastro-
intestinal Tumour Study Group (unpub-
lished) has analysed initial results of a
randomized controlled study which com-
pared: (1) high-dose postoperative radiation
therapy, (2) 5-FU plus MeCCNU, and (3) the
combination of postoperative radiation ther-
apy and 5-FU plus MeCCNU. A 4th arm in
this study was surgery alone. With 187
patients enrolled in this study, clear benefit
from adjunctive therapy has been demon-
strated. The relapse rate in the patients
treated with surgery alone was 52% vs 21%
in patients treated with chemotherapy plus
radiation, 39% in patients treated with
chemotherapy alone and 32% in patients
treated with radiation alone. The median
follow-up of all patients in the study was 118
weeks. The 75% disease-free survival in
weeks was 50 for the control arm, 78 for the
chemotherapy arm, 71 for the radiation arm
and the 75% survival had not been reached
in the chemotherapy plus radiation arm.
There was also a striking decrease in local
recurrence in the patients receiving chemo-
therapy plus radiation. In this arm, only
3% ofpatients demonstrated local recurrence,
compared to 23% in the chemotherapy arm
and 15% in the radiation arm. This study is
continuing to accrue patients to the 3 treat-
ment arms to obtain information on which
arm is superior in overall survival and
disease-free survival. The importance of this
study is that it is a prospectively controlled
trial which has clearly shown that adjuvant
treatment after rectal resection is superior
to surgery alone. Thus, this approach will
have to be considered the treatment with
which future experimental treatments of
rectal cancer will be compared.
The active investigation of non-surgical
management in both advanced, locally
advanced and surgically resected gastro-
intestinal cancers is beginning to show sub-
stantial benefits both in palliation ofpatients'
symptoms and improvement in survival. It
is clear that continued active investigation
will result in even more striking benefits to
the patients afflicted with these diseases.
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SELECTION, EVALUATION, AND DEVELOPMENT OF ANTITUMOR DRUGS
AND THEIR RELEVANCE TO THE CLINIC
A. GOLDIN
Fronm the Divisiont of Cancer Treatment, National Cancer Institute, U.S.A.
The primary objective of preclinical anti-
tumour drug-testing programmes is to select,
evaluate and develop materials from the
universe of synthetic and natural substances,
that will have the greatest likelihood of use-
fulness in the treatment of clinical neo-
plasia. Historically, there has been a reason-
able measure of success in the identification
and introduction of useful antitumour agents
to the clinic, even though the experimental
systems used in the screening were chosen
and utilized primarily on an empirical basis.
Cancers for which drugs have been respon-
sible for some of the patients achieving a
normal life span include acute lymphocytic
leukaemia (pediatric) acute myelogenous
leukaemia (adult) Hodgkin's disease, diffuse
histiocytic lymphoma, nodular mixed lym-
phomas, Burkitt's lymphoma, Ewing's sar-
coma, rhabdomyosarcoma, Wilms' tumour,
choriocarcinoma, testicular cancer and ovar-
ian cancer. However, these responsive
tumours constitute only a small fraction of
the various types of cancer, and there is a
need for new and highly effective drugs for
the treatment of clinical solid tumours.
Over the years, there has been the important
concern at the Division of Cancer Treatment
(DCT), National Cancer Institute (NCI)
screening and drug development programme
that the test models relying heavily on
leukaemias L1210 and P388, with Lewis lung
carcinoma and B16 melanoma as additional
systems, might not be identifying com-
pounds that would be most active against
human solid tumours. With the demon-
stration that human tumours could be trans-
planted and grown progressively in athymic
mice with retention of original biological
characteristics, and with the development of
new animal models, and based on broad
experience, both at the NCI and abroad,
re-examination of the procedures and con-
cepts ofantitumour drug selection, evaluation
and development seemed in order.
As a result, in 1976, the DCT NCI, decided
to reorganize its entire screening programme
with the incorporation of a prescreen (leu-
kaemia P388), and a bypass system for candi-
date agents of interest because of activity in
either other screening programmes or in
selected biochemical or biological assays.
P388 actives and the bypass compounds are
tested in a panel of tumours, including well
established conventional experimental tum-
our systems, more recently developed animal
solid-tumour models and human tumours
growing as xenografts in athymic mice. The
new programme is considered as a compre-
hensive and co-ordinated prospective screen-
ing experiment for which specific questions
are addressed to the screen as follows:
(1) Does the new screen increase the yield
of true positive compounds (active in both
screen and clinic)?
(2) Does extensive and/or broad spectrum
activity in the screening panel increase the
probability of clinical antitumour effective-
ness?
(3) Do human tumour xenografts and
animal tumour screens select the same or
different drugs?
(4) Are the xenograft positives more active
in the clinic than those selected by animal
screens?
(5) Does the screen reduce the number of
false positives (active in the screen but not
active inthe clinic)?
(6) Does it reduce the number of false
negatives (inactive in the screen, but active
in the clinic)?
(7) Is there a correspondence of activity
against animal tumours and/or human tum-
our xenografts with activity against clinical
tumours for specific histological types or
specific organs?
(8) Are compounds that bypass the P388
prescreen, because of special characteristics,
more effective in the screening panel and in
the clinic than compounds initially selected
by the prescreen?
(9) What contribution will the new screen-
ing panel make to prediction of clinical
effectiveness of new drugs with respect to
structure-activity analysis, analogues of
known antitumour agents, and mathematical
approaches to activity prediction?
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The new screening programme will be
described, data presented on compounds
emerging from the screen, and the answers to
the questions addressed to the new screen will
be reviewed.
Once a compound has been determined as
having significant activity against one or more
of the target models, it is subjected to fur-
ther evaluation and development in pro-
ceeding to the clinic. Various systems that
may be used for further evaluation of anti-
tumour agents, and preclinical principles for
improvement of selectivity, will be discussed
and examples cited. These take into account
the complexity of interrelationships of the
triad of host, tumour and drug.
The programme of drug development,
involving decision making in a linear array of
steps, will be described.
The primary theme is that a screening,
evaluation and development programme
should be considered as a dynamic entity
subject to investigation and change in the
search for new and more effective antitumour
agents.
THIRD ALEXANDER HADDOW MEMORIAL LECTURE
Magic Bullet or Tragic Bungle: Problems in Transition of Anticancer Drugs from
Laboratory to Clinic
Professor K. HELLMANN
Imperial Cancer Research Fund, Lincoln's Inn Fields, London
HYPOXIC CELL SENSITIZERS IN RADIATION THERAPY
G. E. ADAMS AND I. J. STRATFORD
From the Division of Physics, Institute of Cancer Research, Sutton, Surrey, England
DESPITE THE many advances in the treat-
ment of cancer by radiotherapy, failure to
achieve local control is still a substantial
problem in some disease sites. Even though
metastatic disease remains a major problem
in cancer therapy, improvements in local
control rates should be reflected in a signifi-
cant reduction in overall cancer mortality.
Although there are various reasons for
local failure in radiotherapy, one of the most
likely is the problem ofhypoxic-cell radiation
resistance.
Hypoxic cells, which are probably present
in most solid tumours, arise as a result of
tumour growth outstripping the blood supply,
and occur usually in and around apparently
necrotic regions of tumours. Hypoxic cells
are believed to be dangerous because of their
radiation resistance. Such cells are in a
resting state and normally would eventually
die of starvation of 02 and other essential
nutrients due to their remoteness from the
blood supply. However, subsequent to, or
during, fractionated radiation treatment,
tumour regression can occur following re-
moval of oxic cells sterilized by the radiation.
This allows some of the radiation-resistant
hypoxic cells to re-oxygenate, enter cycle
and permit regrowth of the tumour. There is
now definite clinical evidence that hypoxia
can contribute to overall radiation resistance
in some human tumours, and during the last
two decades several approaches have been
made to overcome this hypoxia problem.
These include unconventional fractionation
regimes (to exploit re-oxygenation) radio-
therapy in hyperbaric 02 chambers, neutron
radiotherapy and chemical radiation sensi-
tizers. The major steps in the transition
from the laboratory to the clinic in the field
of chemical sensitizers will be outlined in the
lecture. This will illustrate the continuous
and systematic development of research
originating in basic radiation chemistry,
progressing through cellular and tumour
radiobiology, pharmacology and toxicology,
to the current situation where widespread
clinical trials of hypoxic cell sensitization are
now in progress.
The generality of the 02 effect in radio-
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biology encouraged the search for other
chemical agents that might act by a similar
mechanism. As a result, many compounds
are now known which are able to act as
"oxygen-mimics" in radiation sensitization.
These include simple aliphatic compounds
containing conjugate electron-acceptor
groups, quinones, various aromatic structures
and, in particular, nitroimidazoles. Some of
these agents, which like 02 act by increasing
the radiation sensitivity of hypoxic cells, are
in contrast metabolically stable and can
penetrate into the hypoxic regions oftumours
in order to sensitize cells at the time of
irradiation.
Radiation sensitization in vitro by nitro-
imidazoles is dependent upon their electron
affinity, and most of these compounds only
act by increasing the radiosensitivity of
hypoxic cells (Adams et al., 1979); well-
oxygenated cells are unaffected. This differ-
ential property remains the main rationale
behind the use of radiation sensitizers in the
clinic. The radiation response of well-
oxygenated normal tissue should not there-
fore be affected. Among the group of sensi-
tizers of most current interest is misonidazole
(MISO). Hypoxic cells irradiated in the
presence of a sufficient concentration of this
drug can be rendered almost as radiation-
sensitive as well-oxygenated cells. Many
studies have now been carried out with a
variety of experimental tumours, including
human tumours growing as xenografts in
immune-suppressed mice. A review of such
data (Fowler & Denekamp, 1979) shows that
marked radiation sensitization occurs in
almost all tumours, indicating that hypoxic-
cell radiation resistance is a common property
of most experimental solid tumours.
It is clear, however, that the extent of
hypoxia can be reduced by re-oxygenation
when the tumours are irradiated with
multiple fractions of radiation. This is
reflected by the reduction of radiation sensi-
tization by MISO when the drug is adminis-
tered with such radiation regimens.
Nevertheless, radiation sensitization still
occurs in most cases demonstrating that
re-oxygenation processes, though reducing
the hypoxic cell population, does not elimi-
nate the problem. This suggests that the use
of sensitizers in the clinic may take some of
the criticality out of the future choice of
fractionation regimens.
Pharmacokinetic studies with MISO in
rodents, dog and man, have shown that the
drug is widely distributed in the body.
Further, it has a fairly long half-life (mouse:
1-2 h, dog: 5 h man 10-12 h) and in both
rodent and human tumours is able to pene-
trate with generally high efficiency into the
regions where hypoxic cells occur (Ash et al.,
1979).
Although MISO is well tolerated in fairly
high doses in man, it is neurotoxic. Many
Phase I and II clinical studies have shown
that a significant proportion of patients
develop a sensory peripheral neuropathy,
usually shortly after the end of treatments
with multiple doses. Most current studies
have indicated that the maximum dose for
the total fractionated treatment should not
exceed 12 g/m2. Since the drug dose given
with each radiation fraction will clearly
depend on the total number offractions given,
choice offractionation is important in clinical
trials with MISO. This has obviously influ-
enced the design of the numerous clinical
trials with MISO now in progress in various
parts of the world. These studies, which
include both conventional and unconven-
tional regimes for radiation fractionation,
will be discussed.
It is now clear, however, that irrespective
of the regimen chosen, the tolerated doses of
MISO are such that tumour levels ofthe drug,
although fairly high, are not sufficient to give
the theoretical maximum radiation sensitiza-
tion. This has encouraged the search for new
drugs which are either more efficient or less
toxic. This search has been aided consider-
ably by the predictive value of electron
affinity. A number of promising new com-
pounds have already been identified which
are more efficient radiation sensitizers than
MISO (Adams et al., 1980).
In parallel with these developments, much
research has been carried out aimed at identi-
fying the reasons for the neurotoxic proper-
ties of these compounds. Results from some
of the experimental and clinical studies will
be described.
Another property ofMISO and other nitro-
imidazoles is their increased cytotoxicity to
hypoxic than to aerobic cells. The mechan-
ism of the cytotoxic action is not related to
the radiosensitization and appears to involve
the anaerobic reduction of the nitro group
in the compound.
It is possible that the presence of hypoxic
cells in tumours may influence the outcome
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of cytotoxic chemotherapy. If so, nitro-
imidazoles may have a part to play in the
combination chemotherapy of cancer. It has
been found in a number of experimental
tumour systems that MISO administered
either simultaneously with, or just before,
treatment of tumour-bearing mice with an
alkylating agent, substantially increases the
anti-tumour effect of the second drug
(Wodinsky et al., 1979; Rose et al., 1980.
This has been found in a variety of tumours
using cyclophosphamide, melphalan or nitro-
soureas in- combination with MISO, or
related nitroimidazoles. Possible mechanisms
of this interesting and potentially useful
effect will be discussed.
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HYPERTHERMIA: MOUSE, MICROWAVES AND MAN
S. B. FIELD
From the MRC Cyclotron Unit, Hammersmith Hospital, London W12 OHS
THE DISAPPEARANCE of tumour after high
fever was reported more than a century ago
Resulting from this observation, hyper-
thermia was induced by injection of bacterial
toxins. Methods for local heating were sought
but these techniques are difficult, and
interest in the possibility of hyperthermic
treatment faded. However, a firm rationale
has now been developed for using hyper-
thermia, and this in turn has stimulated
further technical developments, so that cancer
therapy by hyperthermia has become of
great interest.
Reasons why hyperthermia might be useful
in treating cancer:
(1) Tumours may become hotter than nor-
mal tissues in a localized treatment field
because of their more sluggish blood supply;
(2) Some neoplastic cells will be intrinsic-
ally more sensitive than the normal cells at
risk;
(3) Tumours contain cells which are:
(a) hypoxic, which seems not to mark-
edly affect their response to hyper-
thermia (in contrast to X-rays) and
(b) at low pH and nutrient-deficient,
both making cells more sensitive to
heat.
(4) Cells in the S phase are particularly
sensitive to heat but relatively resistant to
X-rays, so that a combined treatment with
hyperthermia and radio-therapy might be an
advantage in some circumstances.
(5) Combining heat with drugs may enhance
the therapeutic effect either by increasing the
drug uptake or enhancing the cells sensitivity
to the drug.
The evidence for these statements is
derived from much experimental work on
cells in vitro and both normal and malignant
tissues insitu.
The effects of heat alone are different from
those of heat as a potentiator of other anti-
cancer modalities, and it is therefore import-
ant to find ways of studying the effects
separately. This may be done without
difficulty on several normal tissues, making
use of qualitative and temporal differences in
response to the different modalities. This is
possible because after radiation most cells
die at mitosis, whereas after heat, non-
dividing cells lyse just as readily as mitotic
cells. Skin, for example, shows radiation
damage as radiodermititis. The injury is
enhanced by moderate hyperthermia but is
qualitatively unaltered. In contrast, severe
hyperthermia rapidly causes tissue necrosis.
Similar separations have been made on intes-
tine and cartilage. Such separations are far
more difficult with cells in vitro or with
tumour responses, because in both these
cases the endpoints are normally measured
as a given number of surviving cells, regard-
less ofthe mode ofcell death.
With heat alone, once the threshold for
injury is reached, a small increase in hyper-SYMPOSIUM PAPERS
thermal treatment (temperature or time) will
cause a dramatic increase in the probability
of tissue necrosis. Because of this, very
careful control of heat delivery and accurate
thermometry are required in the clinic. For
heat alone it is found with a wide range of
cells and tissues that a change in temperature
of 1°C is equivalent to a 2-fold change in
heating time.
In clinical practice it is likely that treat-
ment will be given in many fractions, as in
radiotherapy. It is therefore important to
gain an understanding of fractionation in
hyperthermia. It has been shown, with cells
in vitro and in animals, that there is a con-
siderable recovery potential between heat
doses but, in addition, heat causes a transient
resistance to subsequent hyperthermia (ter-
med thermotolerance). This is an extremely
large effect, such that a second treatment
may have to be more than doubled to pro-
duce a specified effect if given after a pre-
vious heating. Thermotolerance manifests
itself in different ways, depending on whether
heat is given as a high temperature for a
short time or as a lower temperature for
many hours (as in the case in whole-body
hyperthermia). The phenomenon is clearly
ofgreat clinical importance and is the subject
of many detailed studies. Thermotolerance
for heat as a potentiator of radiation damage
appears to be much less than for direct heat
injury, illustrating the difference in mechan-
ism between heat enhancement of X-ray
injury and direct heat damage.
Ifheat enhancement ofradiation damage is
greater for tumours than for normal tissues,
there will be a therapeutic advantage in
using a combined treatment. Thermal
Enhancement Ratio (TER) does not vary
widely between different normal tissues. It
tends to be greater if heat is given before
X-rays and also tends to be higher for larger
doses per fraction. Unfortunately the possi-
bility of a therapeutic gain has been difficult
to ascertain experimentally owing to the
problems of uniformly heating tumours (or
even normal tissues). This has been illus-
trated in experiments on mouse tumours and
on exteriorized mouse intestine.
The interaction between heat and X-rays
fades when they are separated in time until
it is lost by 4-5 h, as illustrated by many
experiments on cells in vitro and on normal
tissues. It is possible that a therapeutic
advantage may be gained by heating 4 or
5 h after irradiation, the rationale for which
will be discussed.
A range oftechniques are now available for
achieving local hyperthermia: ultrasound,
micro or radiofrequency waves. The inter-
action of electromagnetic radiation with
biological materials depends on the frequency,
the method of application and on biological
factors. Suitable non-invasive temperature
measurements have not yet been developed
and even invasive techniques are not simple.
However, despite these difficulties, clinical
results are extremely encouraging. Tumours
in man and other large animals appear to
become hotter than normal tissues, very few
complications have been reported and a
number of highly optimistic clinical reports
are appearing in the literature
TREATMENT OF ACUTE LEUKAEMIA BY WHOLE-BODY IRRADIATION AND
MARROW TRANSPLANTATION: 25 YEARS FROM MOUSE TO MAN
P. ALEXANDER
From the Institute of Cancer Research, Clifton Avenue, Sutton, Surrey, England
NINETY PER CENT of patients with acute
myelogenous leukaemia (AML) who have
attained a complete clinical remission by
treatment with chemotherapy relapse with
and die of leukaemia. Thomas et al. (1979)
at Seattle have shown that if patients in
remission are given a single treatment of
total body irradiation (TBI) at high dose
(, 10 Gy) together with a short course of
chemotherapy, the incidence of relapse falls
to less than 200o. This procedure requires
that the lethally damaged marrow of the
patient is restored by a transplant from a
normal donor whose marrow, unlike the
patient's, does not harbour leukaemia cells.
The concept that leukaemia might be treated
in this way arose from experiments carried
out by Barnes et al. (1956) at the Radio-
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biological Laboratories at Harwell, which
showed that a murine leukaemia could be
eradicated by supralethal TBI (but not by
lower doses which allowed some of the
animals to survive the effects of irradiation)
and that the mice could be rescued by a
marrow graft. Twenty-two years have
elapsed between these first animal experi-
ments and the introduction of an acceptable
clinical protocol. This was not because
physicians were slow off the mark. Indeed,
within one year of the Harwell publication,
Thomas et al. (1957) reported on the problems
encountered in trying the procedure in
patients, and his group decided to abandon
clinical trials in favour of an extensive
laboratory programme ofmarrowtransplanta-
tion in dogs exposed to TBI. In Paris, Mathe
had similar dismal results in patients, but
persevered until 1963 because allografts of
marrow given in Paris were held responsible
for saving the lives of 4 scientists who had in
1959 been accidentally exposed to high
doses of irradiation in a reactor accident in
Yugoslavia. Initially, they were thought to
have received a lethal dose of radiation,
but a careful reconstruction of the accident
some years later suggested that the dose had
been overestimated and their survival need
not be attributed to the inoculation of
marrow.
To reach the present state of clinical
application, many problems had to be re-
solved which required careful investigative
work, technological innovations (such as
blood-cell separators to provide cells for
support) and the development of new anti-
bacterial agents. However, the major barrier
to success and one often pronounced insoluble
was graft-versus-host-disease (GvHD). Con-
temporaneous advances in histocompatibility
typing allowed the Seattle group to select
donor-recipient combinations in which GvHD
could be prevented by cytotoxic drugs in
half of the patients. The GvHD prophylaxis
used at Seattle was based on a mouse model
first described by Uphoff (1958), but it
needed much development initially in dogs
and then in man. Even so GvHD was
associated with the 40% mortality which this
treatment carries in the group of patients
selected fortreatment (i.e. young, in remission
and with a matched donor).
The chance discovery by Sandoz in
Switzerland of an antibiotic Cyclosporin A
with a unique immunosuppressive action
(Borel et al., 1976) had a dramatic impact on
GvHD. Work carried out in the last two years
in England (Powles et al., 1980) indicates that
this new agent virtually eliminates GvHD
as a clinical problem where the donor mar-
row is adequately matched, and may even
make mismatches possible. To stop GvHD
the patient has to be immunosuppressed, but
most immunosuppressants interfere with cell
division, and in marrow grafts can only be
used at low doses if they are not to destroy
the newly proliferating marrow. The reason
for testing Cyclosporin A for marrow grafting
was that it is immunosuppressive without
being myelotoxic.
The end of the story has not yet been
reached. Radiobiology in the early 1950's
raises the spectre of numerous possible late
effects, of which a wasting syndrome asso-
ciated with progressive lymphoid atrophy
may be the most worrying. There are many
other challenging questions, such as whether
an immunological mechanism contributes to
the destruction of the leukaemia, or whether
this is wholly due to TBI. Is AML uniquely
radiosensitive or is it possible that other
disseminated malignant diseases may be
treated in the same way? Clinically, the
procedure cannot yet be offered to the more
elderly patients, and much attention will
have to be devoted to reducing toxicity.
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THE DEVELOPMENT OF INTERFERON AS AN ANTI-CANCER AGENT
N. B. FINTER AND K. H. FANTES
From The WVellcome Research Laboratories, Beckenham, Kent, England
INTERFERONS ARE members of a family of
proteins with enormous biological activity
(one antiviral unit corresponds to 1-8 mg)
and a variety of effects on cell functions.
Although discovered as long ago as 1957,
their value in medicine largely remains to be
established. Studies in the 1960's confirmed
that appropriate interferons could protect
animals against a widevarietyofexperimental
infections with viruses, including known
tumour viruses (Finter, 1973). Unexpectedly,
it was found that the incidence or growth of
carcinogen-induced, transplanted and spon-
taneously arising tumours of animals could
also be influenced by interferon (Gresser &
Tobey, 1978). The possible mechanisms
involved in these anti-tumour effects will be
discussed.
The evaluation of interferon in man has
been frustrated by the shortage of suitable
material. In consequence, it has so far only
been possible to treat small numbers of
patients in uncontrolled studies. Most of the
interferon used has been made from buffy-
coat cells collected from transfused blood.
Some of the results obtained in cancer
patients with the rather crude resulting prod-
uct (HuIFNj) have been encouraging. Other
sources of interferon for clinical use include
human diploid fibroblasts (yielding IFNf6)
and human lymphoblastoid cells (mainly
IFN,); these latter can be used for production
on a commercial scale. Genetic engineering
techniques may provide limitless quantities
of interferon proteins. It remains to be
proved whether the resulting individual and
non-glycosylated interferon proteins will
mirror the effects of the mixture of proteins
obtained from cultured human cells.
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ADENOCARCINOMA OF THE OVARY
-THE ROYAL MARSDEN HOSPITAL
EXPERIENCE 1969-73. A. VILARDO and
and THE OVARIAN CANCER GROUP (V. M.
Dalley, J. Baker, C. L. Harmer & E. Wilt-
shaw)
A review of 324 cases of adenocarcinoma of
the ovary seen at the RHM between 1969
and 1973 is presented. Three treatment
policies were followed for early-stage (I & II)
disease: (a) no post-operative treatment,
(b) pelvic radiotherapy, and (c) abdomino-
pelvic radiotherapy. Overall 5-year survival
was related to stage, and 69%, 39%, 3.70o
and 0% were recorded for Stages I-IV
respectively. Well differentiated tumours
did better than poorly differentiated ones,
and there was some indication that in Stages
I and II abdominopelvic irradiation was
better than pelvic irradiation alone, which
in its turn was better than no post-operative
treatment. This study describes the back-
ground for our present trials in all stages of
the epithelial tumours of the ovary.
PROGNOSTIC VARIABLES IN CAR-
CINOMA OF THE OESOPHAGUS. R.
Cox, C. E. NEWMAN, E. CLARIDGE & H. R.
MATTHEWS, Departments of Clinical Oncology,
Medical Physics and Biomedical Engineering,
Queen Elizabeth Hospital, Birmingham, B15
2TH, and Department of Thoracic Surgery,
East Birmingham Hospital, Birmingham B9
5ST
Fifteen variables were assessed at presenta-
tion in 100 consecutive patients with carci-
noma of the oesophagus. These patients were
then followed up for a minimum of one year
to determine which of the variables are of
prognostic significance.
Differences in median survival of > 100
days were found with the following variables:
complete resection vs all other treatments,
the decision to explore or palliate, presence
or absence of a coexistent medical condition,
high or moderate physical status, absence or
presence of a post-operative complication,
minimal dysphagia vs moderate or severe,
and the sex of the patient (median survival is
longer in women).
Analysis of survival by the Life Table/Log
Rank method showed the following to be
highly significant variables (P<0.001) opera-
49
tion, presence or absence of post operative
complication, decision to explore or palliate,
physical status and performance status.
Significant variables (0.05>P>0-001) were
coexistent medical condition, age, histology,
weight loss, degree ofdysphagia and presence
of secondary spread. Not significant were
sex, presence of painful dysphagia, duration
of symptoms and the site of the tumour.
Some of these variables are inter-related.
At present only 5% of all patients with
carcinoma of the oesophagus survive 5 years.
Chemotherapy may be of value in improving
the prognosis and this will be tested in clinical
trials. Design of such trials will require a
knowledge ofprognostic variables.
ISOELECTRIC FOCUSING OF OEST-
RADIOL RECEPTOR PROTEIN FROM
HUMAN MAMMARY CARCINOMA-
A COMPARISON WITH THE DEX-
TRAN-COATED CHARCOAL ASSAY.
E. J. LLOYD, D. M. BARNES & L. G. SKINNER,
Clinical Research Laboratories, Christie Hos-
pital and Holt Radium Institute, Manchester
M20 9BX
A laboratory method for the detection of
oestradiol-17/ receptor protein (REc) in
breast tumour tissue by isoelectric focusing
(IEF) in polyacrylamide gel (Gustafsson et al.,
1978, Cancer Res., 38, 4225) was investigated.
The results obtained by this method were
compared to those from the dextran-coated
charcoal method (DCC) (Korenman & Dukes,
1970, J. Clin. Endocrinol, 30, 659). The
estimation of RE, by IEF may have con-
siderable clinical importance as RE, can be
detected by this method in tissue samples
-% the wet weight normally considered
minimal for DCC analysis. The method may
therefore be suitable for Tru-cut and Fine-
needle biopsy samples.
Amodified IEF method was used to investi-
gate 32 cytosols prepared from unselected
breast-tumour tissue. The results, when
compared with DCC results obtained on the
same cytosol, agreed on the presence or
absence ofreceptors in 97%O of cases. Quanti-
tative analysis of the positive results showed
a correlation coefficient of 0588 (P<0001).
However, IEF gave significantly lower recep-
tor concentrations than the DCC method.
Twenty-six Tru-cut biopsy tumour specimens
were pre-incubated with radioactive oestra-
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diol and analysed for receptor by IEF. The
results were compared with those obtained
by the DCC method on the same tumour. In
88%O of the specimens examined both
methods agreed as to the presence or absence
of RE,. A correlation coefficient, of 0-62
(0-01 <P<0-02) was calculated from the 15
positive results. There was no significant
difference between the results from the two
methods. Quantitative results were related
to total protein concentration in the cytosol.
Negative receptor status was defined as
< 5 fmol/mg protein for 1oth methods.
CYTOSOL OESTROGEN AND PRO-
GESTERONE RECEPTORS, NODE
STATUS AND EARLY RECURRENCE
OF PRIMARY BREAST CANCER. J.
M. T. HOWAT, M. HARRIS, R. SWINDELL &
D. M. BARNES, Christie Hospital and Holt
Radiunm Institute and Withington Hospital,
Manchester M20
Recent papers have emphasized the value of
the measurement of cytosol oestrogen recep-
tors (RE,) in primary breast tumours as a
predictor of early recurrence, (Knight et al.,
1977; Maynard et al., 1978; Cooke et al.,
1979); the clinical application of proges-
terone receptor (RP,) estimations is less
clear.
This is a preliminary report on RE,
measured in tumour cytosols from 175
patients treated by modified radical mastec-
tomy in whom there was histological proof of
the presence or absence of axillary node
involvement. At a median follow-up of 24
months (range 1-48 months) the occurrence
rate was significantly lower in patients whose
tumours were RE+ than in those whose
tumours were RE- (P=0-02, 102E+ ; 73E-).
There was no difference in the recurrence
rates of RP+ and RP- tumours. The overall
recurrence rate was significantly higher in
node-positive patients regardless of the
receptor status (P< 0-001) none the less a
significant improvement in disease-free inter-
val was seen in RE+ patients when node
status was taken into account (P=0045).
When analysed with regard to the degree of
node involvement it was only those patients
with few nodes (1-3) who benefited by having
RE, for they had a significant improvement
in the disease-free interval when compared
with RE- patients (P=0-049. 21+. 17-).
No significant difference in recurrence rate
was seen in node-negative patients (P=0-913.
62+; 38-) nor in those with more than 4
axillary nodes (P=0.286, 19+; 18-).
Although the follow-up is short this study
confirms that measurement of RE may
provide useful prognostic information, but
they cannot be considered in isolation and the
importance of axillary-node involvement
should not be underestimated.
ELASTOSIS IN HUMAN BREAST
CANCER AND RESPONSE TO ENDO-
CRINE THERAPY. J. R. W. MASTERS*,
R. R. MILLISt, R. J. B. KINGt, M. MINTONt
& R. D. RUBENSt, *Institute of Urology, St.
Paul's Ho:spital, London, WC2, tlmperial
Cancer Research Fund Breast Cancer Unit,
Guy's Hospital, London, SE1 and tICRF,
Lincoln's Inn Fields, London, WC2
The amount of elastosis in primary breast
tumours was found to be associated with
response to endocrine therapy in a prelimin-
ary study of a small series of cases (Masters
et al. (1979) Br. J. Cancer, 39, 536). In order
to confirm this finding in histological sections
from the primary tumours of 245 patients
with advanced breast cancer, elastosis w"as
subjectively assessed as absent. present in
small or moderate amounts, or present in
gross amounts. The patients received a total
of 289 endocrine treatments assessable using
UICC criteria (oophorectomy, 38; ovarian
irradiation, 22; androgens, 45; oestrogens,
37; hypophysectomy, 32; tamoxifen, 115).
In the women whose tumours did not contain
elastosis there were 8/56 (14%) responses, in
contrast to 13/31 (420o) in those with gross
elastosis (see Table). The assessment of
elastosis is a simple exercise which requires
no additional material, and these data con-
firm that there is an association between
elastosis in primary breast tumours and the
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IS THERE POLYMORPHIC META-
BOLISM OF AMINOGLUTETHIMIDE
IN MAN? S. J. HARLAND, R. C. COOMBES,
M. JARMAN, E. C. NICE & A. B. FOSTER,
Institute of Cancer Research and Ludwig
Institute of Cancer Research, Sutton, Surrey
Aminoglutethimide (AGT) inhibits the syn-
thesis of corticosteroids in man and is used in
advanced breast cancer as a means ofachiev-
ingamedicaladrenalectomy. Sinceaprincipal
metabolic reaction for this compound is
N-acetylation (Douglas & Nichols, 1972, J.
Pharm. Pharmacol., 24, Suppl. 150) it is of
interest to determine whether there is a
bimodal distribution for the rate ofthis path-
way in the population as is the case with a
number ofotherdrugs whichareN-acetylated.
Nine fasting volunteers, 5 rapid and 4 slow
acetylators, took a 250 mg tablet of AGT,
gave blood samples and collected urine for
the next 24 h. Analysis of plasma for AGT
and its N-acetyl derivative by HPLC revealed
(1) no difference between the two groups in
the levels of the parent compound at 0-5,
2 and 8 h after its administration, and (2) the
levels of N-acetyl AGT were significantly
higher in the rapid acetylators at the 3 times
(means of 1-06, 1922 and 1-05 ,ug/ml, respec-
tively). The clinical importance of this find-
ing is being currently investigated. Other
studies have shown that there is no stereo-
selective metabolism of the enantiomers of
AGT. Nitroglutethimide has been identified
as a urinary metabolite by GC-MS. This
metabolite may be of toxicological signi-
ficance.
CLINICAL EXPERIENCE WITH ORAL
HIGH-DOSE METHOTREXATE. D. J.
FORECAST, B. MUNDAY & A. HOWELL,
Departments ofMedicine and ClinicalPharma-
cology and Therapeutics, University of Bir-
mingham, Edgbaston, Birmingham
Oral methotrexate MTX may give compar-
able concentration-time curves to infusions
if the dose is subdivided. It may be given on
an outpatient basis, thus saving the expense
of hospital admission and patient time.
(Bell et al., 1978 Br. Med. J., i, 857). Since
tumours may recur between courses ofchemo-
therapy, the aim of this study was to test the
safety and absorption of oral MTX given to
out-patients between conventional courses of
i.v. chemotherapy. Twenty-seven patients
(9non-Hodgkin's lymphoma(NHL),5bladder,
7 teratoma, 5 gynaecological malignancy and
one head and neck) were given a total of 125
courses. Multiple blood samples were taken
over 48 h to testabsorptionduring 20ofthese.
MTX regimes were, 8 x 50 mg 2-hourly, or
4 x 100 mg 5-hourly, or 4 x 50 mg 5-hourly,
all with leucovorin rescue at 24 h (6 x 15 mg
6-hourly).
There was no systemic toxicity or treat-
ment delay due to haematological toxicity in
patients with NHL (CHOP, MTX given on
Day 14 of 28-day cycle), bladder carcinoma
(cis-Pt, MTX on Day 10 and 17 of 21-day
cycle) or amongst 7 patients given MTX
alone (one NHL, 5 gyn., 1 head and neck).
However, there were 5 episodes of oral
ulceration and 7 of low white count (4-0 x
109/1) in 9 of the 47 courses given to tera-
toma patients oncis-Pt and VP-16 over5 days
with MTX on Day 10 and 17.
Areas under curves for the 3 dose sched-
ules were: 8 x 50 mg, 26,023 +6876 ng. h/ml
(n=6); 4 x 100 mg, 24,624 + 9195 ng. h/ml
(n=5) and 4 x 50 mg, 14,391 + 7644 ng. h/ml
(n=5). Two patients sampled during several
cycles showed no appreciable fall off in
absorption with time. We conclude that the
toxicity of oral high-dose MTX is acceptable,
and that absorption occurs between cycles of
i.v. chemotherapy.
HIGH-DOSE MELPHALAN INADVAN-
CED MALIGNANT MELANOMA. G.J. S.
RUSTIN, M. A. CORNBLEET, D. W. HEDLEY
& T. J. MCELWAIN, Department of Medicine,
The Royal Marsden Hospital and Institute of
Cancer Research, Downs Road, Sutton, Surrey,
England
Twenty-seven patients with symptomatic or
life-threatening metastases from malignant
melanoma were treated with high-dose mel-
phalan (> 140 mg/M2) and autologous mar-
row rescue. Fourteen of these patients also
received cyclophosphamide (500 mg) i.v. 7
days before the melphalan. These manoeuv-
res reduced the gut and marrow toxicity of
the melphalan, so that doses ofup to 260 mg/
m2 could be tolerated. Objective tumour
regression was obtained in 20/27 (74%) ofthe
patients with 12/27 (44%) showing a decrease
in the product of 2 diameters of all measur-
able lesions of >5000 of whom 2/27 (7%)
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entered complete remission. This compares
with a regression rate of only 900 when con-
ventional doses of melphalan are used (Luce,
1972, Cancer, 30, 1604). Overall there was no
survival benefit for those whose tumours
regressed compared to those with no response.
However, life-table analysis showed that
median survival for the 9 patients who
received >200mg/M2 of melphalan having
previously been primed was 11 months from
treatment and 14 months from dissemination,
compared with 3 and 8 months respectively
for those who received <200 mg/M2 of
melphalan.
Although survival from dissemination in
this treated group is longer than in other
published series, we would not advocate high-
dose melphalan in melanoma except as pal-
liation in patients with severe symptoms.
However, the response rate and survival data
do suggest that this treatment might form
the basis of combination therapy. We are at
present investigating its combination with
misonidazole, and its use in the treatment of
other tumours.
THE PATHOGENESIS AND CONTROL
OF INTERFERON-INDUCED PY-
REXIA. T. J. PRIESTMAN & R. LUCKEN,
Wellcome Research Laboratories, Beckenham,
Kent
Recent papers have reported the use of
leucocyte and fibroblast interferon (IFN) in
the treatment of advanced cancer. In all
studies, pyrexia was seen after initial doses
of IFN. The material used in these trials was
only 0-1 1% pure, and it has been suggested
that fever was caused by non-IFN protein.
In a study with lymphoblastoid IFN (HLBI),
some 20-50 times purer than IFN used in
previous clinical series, pyrexia was initially
dose-limiting (Priestman, 1980, Lancet, ii,
113). The possibility ofendotoxin contamina-
tion was excluded by negative Limulus
lysate assays, chick-embryo toxicity, and
rabbit pyrogenicity tests. The clinical and
laboratory data indicated that IFN-induced
fever was mediated by the release of endo-
genous pyrogen. A subsequent clinical trial
showed that pretreatment with salicylates
reduced the degree of fever after HLBI
administration. It is concluded that IFN is
inherently pyrogenic, causing the release of
endogenous pyrogen, and that salicylate
therapy will reduce the fever until tolerance





HISTOLOGICAL TYPE. R. BELL, C. J.
GALLAGHER, J. FORD, J. S. MALPAS & T. A.
LISTER, ICRF Department of Medical Onco-
logy, St. Bartholomew's Hospital, London EC1
Twenty-one consecutive untreated patients
with non-Hodgkin's lymphoma (NHL) of
unfavourable histology were treated between
May 1978 and August 1979. Fifteen males
and 6 females, median age 55 years old (range
18-70) were of the following histological
groups (Rappaport) diffuse histiocytic 15,
diffuse undifferentiated 6, immunoblastic 8,
lymphoblastic 3, centroblastic 3, malignant
histiocytosis 3 and other high-grade 4. All
but one had Stage IV disease wvith a mean of
2-2 sites of extranodal involvement per pt.
These included: liver 10 pts, marrow 7, gas-
trointestinal 7, lung 5, bone 4, soft tissues 4,
testes 2, pericardium 2, urinary tract 2 and
oropharynx 1, superior venacaval obstruction
4 pts. High-dose combination chemotherapy
was given as cyclophosphamide 2-5 g/m2 i.v.,
Adriamycin 50 mg/M2 i.v., vincristine 2 mg
i.v., methotrexate 12-5 mg i.t. and daily
prednisolone 1 g/m2 i.v. x 5 (CHOMP), re-
peated every 3-4 weeks for a minimum of 6
courses. Ten pts received full doses and 11
reduced doses, because ofhaematological and
gastrointestinal toxicity. There were 7
responders (33%o overall) of which 4 were
complete responses, 2 partial responses with
minimal X-ray abnormalities and one failure
who entered CR after cranial and abdominal
radiotherapy. All responders are alive with-
out relapse for a mean period of 17-0 months
(range 12-24-7) with a mean duration of
remission of 10-6 months (range 6-2-14).
Six pts failed to respond and died with
resistant disease and infection. Four pts
died of infection during remission induction
wNith responding disease, and four others died
in their first cycle of treatment, one of infec-
tion, one of gastric haemorrhage, one of
myocardial infarction and one of severe
metabolic disturbance. A more intensive
programme has doubled the survival (33%o)
of our Stage IV unfavourable histology pts
(Lister et al., 1978, Cancer Chemother. Rep.,
1,107).
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TUMOUR IMPLANTS IN MOUSE
EARS: A MODEL FOR LATE IRRADIA-
TION EFFECTS ON TUMOUR VAS-
CULATURE. J. SHEWELL, Radiobiology
Department, St Bartholomew's Hospital Medi-
cal College, London
The thinness of the mouse ear allows direct
observation of its blood vessels, a property
used in studying vascular damage after irradi-
ation (Bakowska & Lindop, 1971, 6th Eur.
Conf. Microcirculation, p. 145; Stearner et al.,
1976, Rad. Res., 65, 351). The developing
vasculature of tumour implants of C3H/Bts
mammary tumours in one ear of C3H/Bts
male mice can also be followed. Late radia-
tion fibrosis of the ear vessels might impair
post-irradiation administration of cytotoxic
drugs. Using this model, it has been shown
that 80 mg/kg methotrexate i.v. produces a
tumour response (Shewell, 1976, Br. J.
Cancer, 33, 210) of 0 6 in both non-irradiated
and irradiated tumours up to 6 mths after
irradiation. After this time, and proportional
to irradiation dose (5-25 Gy 220 kVp X-rays)
i.v. methotrexate is increasingly ineffective on
irradiated implants. Thistimingcoincideswith
thedevelopment ofmorphological vascularab-
normalities in the irradiated non-tumour ear.
INHIBITION BY MATURING GRANU-
LOCYTES OF THE REGENERATION
OF HAEMOPOIETIC PROGENITOR
CELLS IN MICE TREATED WITH
COMBINATIONS OF CYTOTOXIC
AGENTS. N. M. BLACKETT, Biophysics
Division, Institute of Cancer Research, Sutton
Studies on the response of haemopoietic
tissue in mice to cytotoxic agents in com-
bination with whole-body irradiation have
shown that the number of maturing granulo-
cytic cells in the marrow has a large inhibitory
effect on the regeneration of the early pro-
genitor cells. A similar effect is observed with
the regeneration of normal marrow cells
injected after the irradiation, indicating that
the effect is the result of a change in the
stimulus for marrow regeneration.
With 3 cytotoxic agents, cyclophosphamide,
cytosine arabinoside and 5-fluorouracil, there
is the same high inverse correlation between
the number of granulocytes with ring-shaped
nuclei at the time of irradiation, and the
subsequent regeneration of stem cells. It
seems likely that these effects are due to the
operation of an important biological regula-
tory mechanism of haemopoietic stem cells
that can be manipulated in ways that could
improve marrow transplantation and chemo-
therapy.
RELATIONSHIP BETWEEN ABILITY
OF TUMOUR CELLS TO AGGREGATE
PLATELETS AND THEIR CAPACITY
TO SEED OUT OF THE CIRCULA-
TION. N. WILLMOTT, A. MALCOLM* &
K. C. CALMAN, *Department of Oncology and
Pathology, University of Glasgow
Two murine tumours, the TLX-5 lymphoma
and Sarcoma 180, were examined for their
capacity (a) to aggregate circulating blood
paltelets as measured by the capacity of i.v.
injected tumour cells to elicit a drop in
platelet count 20 min after injection and (b)
the anatomical distribution of tumour depos-
its in mice sacrificed when the morbid effects
of an i.v. injection of tumour cells became
evident. It was found that administration of
up to 2 x 10 TLX-5 lymphoma cells failed to
elicit platelet aggregation, and at necropsy
tumour deposits were detected histologically
in spleen, liver and kidney. In contrast,
1-5 x 106 in vivo grown Sarcoma 180 cells
elicited platelet aggregation and at necropsy
tumour deposits were detected only in the
lungs. If, however, Sarcoma 180 cells were
grown in tissue culture they lost their ability
to aggregate platelets and also their capacity
to form tumour deposits after i.v. injection.
These observations are consistent with the
hypotheses that (a) platelet aggregation is
important in the seeding out of tumour cells
from the circulation and (b) tumour cells
that are not adapted for existence in the
asocial environment of the blood stream may
be destroyed if confined there.
LECTIN AGGLUTINABILITY OF
MAMMARY TUMOURS WITH DIF-
FERING METASTATIC COLONIZA-
TION POTENTIALS. J. E. PRICE & D.
TARIN, Department of Histopathology, John
Radcliffe Hospital, University of Oxford
Lectin agglutinability has been used in this
investigation as one means of comparing the
surface composition of cells from tumours
with high and low pulmonary colonization
potential. As in our previous work, we have
used only primary (i.e. naturally occurring)
721BACR AND RSM JOINT MEETING
mammary tumours in mice. These were dis-
aggregated with collagenase to obtain a
single-cell suspension and the metastatic
colonization potential assessed by reinocula-
tion via the tail vein into the donor and
batches of 5 syngeneic animals. Aliquots
from the same cell suspension were studied for
lectin agglutinability on the same day.
Debris and red cells were removed from the
aliquots by density-gradient centrifugation
on Percoll, and the rate and degree of agglu-
tinability assessed by measurement of the
disappearance of single cells from suspension
with a Coulter counter linked with a C-1000
channelizer. It was found that agglutin-
ability with the lectins Concanavalin-A and
wheatgerm agglutinin bore no relationship to
the pulmonary colonization potential of the
primary mammary tumour. However, studies
on disaggregated secondary deposits from
tumours which manifested high colonization
potential were consistently less agglutinable
than the cells of the primary tumours from
which they were originally taken. Further
investigation is now in progress to examine
whether this difference is due to a selection
process during dissemination or to site-
induced changes in the cells which lodge in
the lung.
METASTATIC PROPERTIES AND
CELL SURFACE GLYCOPROTEINS OF
A HAMSTER TUMOUR OF HSV AETI-
OLOGY AND ITS TWO METASTATIC
SUBLINES. R. C. REES & J. R. WALKER,
Department of Virology, The University of
Sheffield Medical School, Sheffield
The acceptance of a realistic animal model
for human malignancy requires that the
tumour should not be highly antigenic or
encapsulated, but that cells should spon-
taneously metastasize to sites distant from
the primary solid mass. Two such metastatic
sublines have been isolated from a hamster
tumour of HSV-2 aetiology (333-2-26).
These metA and metB lines were established
by in vivo s.c. transplantation of lung meta-
static foci which occurred at low frequency in
hamsters after resection of the primary
tumour. Both lines were considerably more
metastaticthan theparent; hamster mortality
due to metastasis was typically 100% 40
days after tumour resection compared with
20% in the parent line.
The efficiency of plating in soft agar of the
parental and metA and metB lines was
assessed; no correlation between anchorage-
independent growth and metastatic potential
was seen. In addition, the cell-surface glyco-
protein profile was analysed by PAGE after
labelling by pretreatment with galactose
oxidase or periodate and borotritiide reduc-
tion. Development of metastatic potential
was correlated with an increase in high-
mol.-wt species of surface glycoproteins
possessing a terminal neuraminic acid and
subterminal galactose residue.
CELLULAR BASIS FOR THE LOSS OF
CARCINOGEN FROM METHYL-
CHOLANTHRENE - IMPREGNATED
MILLIPORE DISCS. M. F. A. WOODRUFF,
J. BARD, A. Ross & G. FORBES, MRC
Clinical and Population Cytogenetics Unit,
Western General Hospital, Edinburgh EH4
2XU i
Millipore discs impregnated with methyl-
cholanthrene (MC) implanted s.c. in mice,
evoke an early intense macrophage and giant
cell reaction. Later, discs become covered
with connective tissue, and eventually fibro-
sarcomas develop. Studies with 3H-labelled
material show that MC is removed from the
discs and rapidly broken down (half life
about 7 days) to a water-soluble product
which is excreted in faeces and urine. Remov-
al of label is halted by whole-body irradia-
tion (5-5 Gy) with the disc area shielded; this
observation, in conjunction with the histo-
logical and autoradiographic findings, and the
paucity of label in cells stripped from excised
discs, suggests that the removal and degrada-
tion of MC depends on macrophages and the
replacement of spent macrophages by new
cells generated centrally. The rate of dis-
appearance of label from implanted 3H-MC
discs was not altered by administration of
Corynebacterium parvum (CP); this however
does not exclude the possibility that the
metabolic pathways involved in the removal
ofMC are altered. To investigate this it is pro-
posed to study, in both normal and CP-
treated mice, the extent to which cytochrome
P450 and other enzymes concerned in the
activation and detoxification of polycyclic
hvdrocarbons by liver microsomal fractions
are inducible in the macrophages which
accumulate in inflammatory exudates. The
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histological techniques used should be readily
applicable to the study of the early stages of
chemical carcinogenesis and the host reaction
to transformed cells.
OBSERVATIONS UPON THE DISTRI-
BUTION OF MAST CELLS IN LYMPH
NODES, DURING THE PROGRES-
SION OF A LYMPHOID LEUKAEMIA
OF THE RAT. S. T. QAZZAZ & R. W.
STODDART, Department of Experimental Path-
ology, Stopford Building, University of Man-
chester, Manchester M13 9PT
Feew previous studies have been made of the
distribution and numbers of mast cells in
lymph nodes in relation to normal and
pathological states. In normal human and
rat nodes, most mast cells are found either at
the margins of the medulla and paracortex
(MMC) or at the outer edge of the node
(CMC) the minority being in the intervening
paracortex (PMC). They are rare in follicular
areas.
During the progression of the Roser
leukaemia in the rat, the MMC disappear
before the lymph nodes are enlarged, or are
histologically abnormal, while the PMC are
lost during infiltration and enlargement. The
CMC are eventually reduced to those remain-
ing in the subcapsular sinus. After ani early
decline, total mast cell numbers rise again in
the terminal stages of the disease.
The results support the view that mast
cells migrate centripetally across lymph
nodes, though the early disappearance of the
MMC is unlikely to be caused by mechanical
obstruction of the node by proliferating
leukaemic cells.
EXTRAVASCULAR NATURAL CYTO-
TOXICITY IN MAN: STATUS OF
LYMPH NODE AND TUMOUR-INFIL-
TRATING LYMPHOCYTES. M. MOORE
& B. M. VOSE, The Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester 20
A major distinction is reported between the
cytolytic activity of peripheral-blood lym-
phocytes (PBL) and that of lymph-node and
tumour-infiltrating lymphocytes (TIL)against
targets of the NK-sensitive K562 cell line
in short-term 51Cr-release assays. In the PBL
of normal donors and lung-cancer patients
in whom disease was advanced, anti-K562
reactivity, though variable, was consistently
detectable, and this activity could be aug-
mented to a similar extent in patients and
controls by treatment of effectors with
exogenous interferon (IF). By contrast,
anti-K562 activity in lymph-node cells (LNC)
and TIL was virtually absent, and significant
levels could not be induced by exposure to
IF. This activity wN-as not attributable to
co-existent suppressor cells for NK function,
since admixture of LNC and TIL with nor-
mal PBL failed to modulate K562 killing by
the latter. The results imply that K562-
reactive NK cells and their precursors may
frequently be present at sub-threshold levels
in the lymph nodes of tumour-bearing
patients, and a similar explanation could
account for the inactivity of TIL. However,
in the latter situation, actively-induced NK
dysfunction in situ incapable of regeneration
by IF, and attributable to presently unde-
fined tumour-associated factors, may also be
involved.
ROLE OF MINOR TRANSPLANTA-
TION ANTIGENS IN CONTROLLING
T-CELL RESPONSES TO H-Y. W.
FIERZ, M. BRENAN, A. MULLBACHER &
E. SIMPSON, Transplantation Biology Section,
Clinical Research Centre, Harrow, Middlesex
Failure to activate the immune response may
account for the growth of some tumours.
Some (e.g. those caused by MSV virus in
mice) are rapidly rejected with concomitant
production of H-2-restricted cytotoxicity.
Others, including "spontaneous" tumours of
unknown aetiology are rarely rejected. We
have used the male-specific antigen, H-Y, as
a model for tumour antigens. Female mice
of some strains are responders, rejecting
syngeneic male skin and/or generating H-2
restricted cytotoxic cells (Hurme et al.,
1978, J. Exp. Med., 147, 758; Miillbacher &
Brenan, 1980, Nature, 285, 34). Mouse
strains ofthe H-2 haplotype can produce good
cytotoxic responses (CBA), a more variable
response (C3H, B1O.BR) or no response
(AKR) (data to be presented).
The difference in responsiveness within
H-2k strains must therefore be due to one or
more of the non-H-2 genes at which they
differ. We are presently testing the possible
role ofminor transplantation antigens.
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LYMPHOCYTES MAINTAINED IN T-
CELL GROWTH FACTOR (INTER-
LEUKIN 2) SHOW ENHANCED CYTO-
TOXICITY FOR HUMAN TUMOUR
CELLS. B. M. VOSE & M. MOORE, The
Paterson Laboratories, Christie Hospital and
lolt Radium Institute, Manchester M1120 9BX
Conditions for the production of supernates
from mitogen-stimulated human lymphocytes
with the capacity to induce proliferation in
long-term MLC or PHA cultures which do
not respond to PHA have been investigated.
These supernates can be used to maintain
lymphocytes in continuous growth with a
doubling time of 48 h. Cells grown from
MLC-stimulated cultures show > 80% SRBC-
rosetting cells, are Fc-, do not show ADCC
activity and have reduced lysis of K562
compared with freshly isolated effectors.
Cultured T cells (CTC) show high lytic activity
against the inducing PHA blasts but not
against autologous or third-party targets.
Similar experiments have been performed
with lymphocytes from the blood, lymph
node, spleen and tumour of cancer patients,
and CTC tested for cytotoxicity against
autologous and allogeneic tumour cells and
the K562 cell line. Cytotoxicity for auto-
logous tumour was found in all samples. This
was accompanied by killing of allogeneic
cells in most instances, but killing of K562
was only rarely demonstrable. These data
would be consistent with a polyclonal expan-
sion of cytotoxic effectors in the samples.
The finding of autologous reactivity suggests
the presence of autorecognitive cytotoxic T
cells in cancer patients with specificity for
tumour. Cloning experiments are currently
in progress to investigate this possibility
further.
GROWTH OF HUMAN BLADDER-
TUMOUR CELL LINES IN AN
IMMUNE-DEPRIVED MOUSE HOST.
K. M. JOy*, R. J. BERRY*, & R. M. HIcKs*,
*Department of Cell Pathology and *Depart-
ment qf Oncology, Middlesex Hospital Medical
School, London W1P 7LD
Mice immunologically deprived by thymec-
tomy, cytosine arabinoside pre-treatment and
whole-body irradiation are known to be
receptive to xenografts from an established
laboratory cell line (Steel et al., 1978) and
human tumour biopsy tissue (Selby et al.,
1980). Such immune-deprived mice have
been investigated as a potential xeno-
transplantation model for neoplastic human
bladder tissue, for use in subsequent studies
on neoplastic transformation in vitro.
Four established tumour cell lines derived
from different transitional-cell carcinomas of
the human urinary bladder were xenografted:
EJ, RT112, T24, and RT4. The tumour cells
were injected s.c. at the rate of 106 cells per
mouse into both immune-deprived mice and
non-deprived controls. EJ cells rapidly pro-
duced tumours in 10/11 mice, while 8/10
mice that received RT112 cells developed
tumours. The T24 cell line produced tumours
in 10/20 mice, and on transplantation of
solid tumour tissue from one ofthese animals
11/12 mice developed tumours. Tumours
arose in 4/6 mice injected with RT4 cells, one
of which was later transplanted into 10 mice
with an 80% incidence of tumour formation.
With all the cell lines tumours were generally
detectable within 10 davs of xenografting,
and viable tumours were maintained in
immune-deprived mice for over 120 days. No
tumour was produced in any of the immuno-
logically competent control mice.
The in vivo growth ofxenografted cells was
assessed by histopathological and electron
microscopical techniques. RT112, T24 and
RT4 tumours displayed a pseudopapillary
growth pattern, while EJ tumours were
poorly differentiated and had a solid pattern
of growth. Tumours from all 4 cell lines
showed similar growth. They exhibited
progression from an encapsulated stage
through capsule infiltration to malignant
invasion. Thisimmune-deprived mouse model
thus appears to be a satisfactory alternative
to the nude mouse as a host for human blad-
der tumour-cell lines.
THE GROWTH OF HUMAN PAN-
CREATIC TUMOURS IN ATHYMIC
NUDE RATS rnu/rnu. G. DAVIES, D.
DUKE, A. G. GRANT, S. A. KELLY & J.
HERMON-TAYLOR, Department of Surgery,
St George's Hospital Medical School, London,
SW17 ORE
The athymic nude rat (rnu/rnu) has been
successfully established as an in vivo model
for the growth ofpancreatic exocrine tumours
derived from a pancreatic exocrine adeno-
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carcinoma maintained in cell culture. S.c.
injections of 3x 107 cells into the anterior
chest wall of 25 animals yielded 21 tumours
(84%) The critical period for the establish-
ment of growth was between 28 and 42 days.
Each tumour grew to a size of 400-600 cm2.
Tumours were successfully transplanted into
further rats, and one pancreatic xenograft
was passaged into nude mice (nu/nu) and
transplanted back into nude rats; the take
rate increased to 9000. Distant metastases
did not occur but when tumours were excised
surgically from nude rats, regrowth of the
primary tumour occurred at the original site.
The xenografts maintained the histological
and cytological characteristics of the original
tumour from which the cell line was derived;
the karyotype of the cell line was also main-
tained in the solid tumour after passage and
transplantation. Successful xenografting of
3 out of 4 primary explants from patients
with pancreatic cancer is also reported. The
athymic nude ratisavaluable complementary
tool to the nude mouse for the study of
pancreatic and other common solid human
tumours, and for surgical and serial sero-
logical studies.
LIMITATIONS OF HUMAN TUMOUR
XENOGRAFTS IN INDIVIDUAL PAT-
IENT DRUG-SENSITIVITY TESTING.
M, BAILEY, A. JONES, D. RAGHAVAN, P.
SELBY, A. SHORTHOUSE, J. GIBBS & M.
PECKHAM, Institute of Cancer Research,
Ludwig Institute for Cancer Research and
Royal Marsden Hospital, Sutton, Surrey
The clinical applications ofthe human tumour
xenograft model are not yet clearly defined.
it has been suggested that this system might
provide a means of testing the drug sensi-
tivity of an individual patient's tumour (The
Nude Mouse in Experimental and Clinical
Research, Academic Press, pp. 450 and 293).
We have reviewed our data on xenografts of
mammary, bronchial and ovarian carcinoma,









mas to assess the practicality of this sug-
gestion.
The table shows the small number of
patients in whom drug-sensitivity testing
could have been performed before the
patient's demise. The reason for this low
figure is that patients with aggressive tumours
had a high xenograft take rate, but died
before testing could be performed, whereas
patients with less aggressive tumours who
survived long enough for drug testing to be
possible had a low xenograft take rate. We
conclude that xenografted tumours are not of
practical value for individual patient drug
testing.
IN VITRO CYTOTOXIC DRUG SENSI-
TIVITY TESTING OF HUMAN
TUMOUR XENOGRAFTS GROWN AS
MULTICELLULAR TUMOUR SPHER-
OIDS. A. C. JONES*t, I. J. STRATFORD*,
P. A. WILSON* & M. J. PECKHAM*t, *Institute
of Cancer Research, tRoyal Marsden Hospital,
Sutton, England
Using a sequential static-spinner culture
system, an attempt has been made to initiate
multicellular tumour spheroid formation from
13 different xenografted human tumours. All
the tumours used had been established in
immune-suppressed mice and were taken
from the second passage onwards.
The range of tumours examined includes
melanomas, ovarian, bronchial arid breast
carcinomas and a teratoma. Data on the
colony-forming ability in soft agar of cells
obtained from disaggregated spheroids have
been obtained in 3 tumours. There appears
to be a marked enhancement of the colony-
forming ability of these cells, compared with
the cells obtained directly by disaggregation
of the tumour from the mouse. Individually
growing spheroids obtained from 4 different
tumours have a range of volume-doubling
times of 2-4-15 days. Cytotoxic drug
testing measurements of growth delay and
Total viable Viable spec. from Serially trans- Usable
spec. implanted untreated patients plantable takes takes (%)
91 91 9 6 (6 6)
46 34 11 7 (20)
37 20 2 (10)
49 48 38 5 (12)
16 8 10 4 (25)
239 201 75 24 (12)
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clonogenic survival have been obtained with
spheroids from a bronchial and a breast
carcinoma.
These results support the idea that multi-
cellular tumour spheroids may be useful as a
solid-tumour model in vitro, suitable for
testing cytotoxic drug sensitivity.
MONOCLONAL ANTIBODIES FROM
MICE BEARING HUMAN TUMOUR
XENOGRAFTS. H. WARENIUS* & K.
SIKORAt, *Department of Radiotherapy, New-
castle General Hospital, Newcastle-upon-Tyne
and tMRC Clinical Oncology and Radio-
therapeutics Unit, The Medical School, Cam-
bridge
We have examined the serological response in
immunosuppressed mice bearing xenografts
of the human colorectal-carcinoma line
HT29R. The serum of such animals con-
tains antibodies which bind to HT29R cell-
membrane components. This antibody acti-
vity cannot be completely absorbed by either
human lymphocytes or erythrocytes, indica-
ting that it may be at least in part directed
against tumour-specific antigens. By fusing
spleens from tumour-bearing animals to an
established myeloma line we were able to
produce 14 monoclonal antibodies which
bound to HT29R. Three of these have been
found to bind specifically to HT29R mem-
branes. A further 4 bind to both HT29R
and other colorectal-carcinoma membranes.
Two of these also bound to a carcino-
embryonic antigen preparation. The remain-
ing 7 bound to membranes from normal
red cells, lymphocytes and colon, as well
as HT29R. The serum of xenograft-bearing
mice was examined for blocking activity
against the specific anti-HT29R antibodies.
This provides a possible method ofmeasuring
tumour load.
SERUM FERRITIN AS A THIRD MAR-
KER IN GERM-CELL TUMOURS. A.
GRAIL, G. BATES, A. MILFORD-WARD &
B. W. HANCOCK, University Department of
Medicine and Immunology, Royal Hallam-
shire Hospital, Sheffield.
Serial measurements of serum ferritin have
been assessed as an additional diagnostic and
prognostic marker in a study of 12 patients
with germ-cell tumours. The standard mark-
ers, serum AFP and ghCG, were also assessed
serially.
A poor prognosis was associated with per-
sistently high levels of serum ferritin and
either, or both, high AFP and ghCG levels.
Falls and maintenance of normal levels of
serum ferritin indicated favourable response
to treatment; rising values were associated
with recurrence of dissemination of tumour.
The metabolic rates of decay of AFP and
/hCG give valuable indications of residual
tumour, when values exceed the normal half-
life values of <5 days for AFP and <24 h
forghCG.
Although AFP and /hCG are useful as
markers in the follow-up of patients, increas-
ing levels suggesting recurrent tumour, falls
to within the normal range do not necessarily
indicate a disease-free state. Chemotherapy
may convert the tumour to a non-marker-
producing form and/or may selectively
eradicate the clone of marker-producing
cells. Due to heterogeneity in metastases,
production of tumour markers from different
sites may vary.
Possible explanations for the high serum
ferritin level in malignancy include reticulo-
endothelial block of iron release, tissue dam-
age and increased synthesis by the tumour.
Even if serum ferritin cannot be classed
specifically as a tumour product, it is useful
in the early detection of recurrent tumour
and extragonadal progression of disease.
LOCALISATION OF HUMAN TU-
MOURS BY EXTERNAL SCANNING
AFTER INJECTION WITH RADIO-
LABELLED ANTIBODY TO AFP. D. S.
FAIRWEATIHER, A. K. HALSALL, K. R. HINE,
A. HOWELL, P. W. DYKES*, A. R. BRADWELL,
J. BLACKBURN & A. READER, Departments of
Medicine, Oncology, Immunology and Medical
Physics, Queen Elizabeth Medical Centre and
*The General Hospital, Birmingham
Alpha-foetoprotein (AFP) is used as a tum-
our marker in germ-cell tumours. This
preliminary study was carried out to assess
whether deposits of these tumours could be
identified by external scanning after injection
of radio-labelled antibody to AFP. The
antibodies to AFP were raised in sheep by
immunization with AFP extracted from
amniotic fluid. After immunoadsorption with
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normal sera the IgG was further purified by
ion-exchange chromatography. Samples were
tested for acute toxicity and pyrogenicity in
rabbits. The purified antibody was labelled
wvith 1311 using the Chloramine-T method.
and injected into the patients after an initial
uneventful test dose. Prior to the scan, the
patient also received 99mTc-pertechnetate
and 99mTc-labelled human serum albumin to
outline the extra vascular space and blood
pool, to allow subtraction scanning.
A total of 15 scans were performed on 12
patients, 10 with malignant teratoma, one
with an endodermal sinus tumour and one
with a seminoma (used as a negative control).
All 9 patients with high serum AFP gave
positive scans; 5 of these at the time of
diagnosis. All abnormal areas were con-
firmed by CT scans and lymphangiography,
although 4 secondary deposits were missed.
Three patients gave normal scans wthen
studied again after successful treatment, and
when the serum AFP had fallen to normal.
A further 5 studied for the first time after
treatment (4 with high serum AFP) gave
positive scans, 3 of which were confirmed by
CT scanning. Two areas of anti-AFP uptake
over the stomach were not confirmed by the
CT scans.
These preliminary results show that it is
possible to identify tumour deposits using
antibody to AFP. Further work is needed,
to establish whether this technique will aid
the staging and management of these treat-
able tumours.
DETECTION OF MAMMARY-CAR-
CINOMA CELLS IN MARROW USING
ANTISERA TO EPITHELIAL-MEM-
BRANE ANTIGEN. D. P. DEARNALEY*,
J. P. SLOANEt, M. G. ORMEROD+,K. STEELEX,
R. C. COOMBES* & A. M. NEVILLE*, *Ludwig
Institute for Cancer Research, tInstitute of
Cancer Research and tRoyal Marsden Hos-
pital, Sutton, Surrey
We have previously described an epithelial-
membrane antigen (EMA) which can be
demonstrated by immunohistochemical ineth-
ods on formalin-fixed, paraffin-embedded
sections of human tissue (Heyderman et al.,
1979, J. Clin. Pathol., 32, 35). EMA is con-
fined to but widely distributed in epithelial
tissues and tumours derived from them
(Sloane & Ormerod, Cancer, in press) and has
been used to detect micrometastases in
histological section (Sloane et al., Br. J.
Cancer, in press).
We have developed a technique using an
alkaline phosphatase conjugate for staining
smears of marrow. Giemsa, Luke's and anti-
EMA preparations were made from 74
posterior-iliac-crest marrow aspirates from
patients with breast cancer. Anti-EMA
staining revealed malignant cells in 15
patients, compared with 7 demonstrated by
conventional methods. The 5 patients with
> 100 EMA-positive cells/smear were all
diagnosed as malignant on Giemsa or Luke's
preparations, but only 2/12 with < 100
positive cells/smear were detected. Ten/24
patients with bone metastases had EMA-
positive smears, as did 4/20 patients with
disseminated disease but without bone in-
volvement. Twenty patients had apparently
localized primary breast cancer, one of
whom had EMA-positive cells in the marrow,
as did one/10 patients thought to be free of
metastases during follow-up. Less than 5
EMA-positive cells were found in the speci-
mens from these patients. This technique
may be capable of detecting micrometastatic
disease in breast cancer, as well as improving
the detection of marrow involvement in
patients with disseminated disease. Further
studies are being undertaken to determine
whether larger quantities of marrow from
multiple sites will enable the detection of
micrometastatic disease in patients with
poor-risk primary breast cancer.
THE VALUE OF RADIOIMMUNO-
DETECTION IN THE MANAGEMENT
OF CHORIOCARCINOMA. R. H. J.
BEGENT, F. SEARLE, G. STANWAY, R. F.
JEWKES, P. VERNON, E. S. NEWLANDS &
K. D. BAGSHAWE, Depts of Medical Oncoloqy
and Nuclear Medicine, Charing Cross Hospital,
London, W6 8RF
There have been a number of recent reports
of radioimmunodetection (RID) of cancer,
whereby tumours are localized by external
scintigraphy after i.v. injection of radio-
labelled antibody directed against a tumour
product. Images of human tumours produ-
cing carcinoembryoniic antigen, human chor-
ionic gonadotrophin (hCG) and alpha-foeto-
protein have been obtained using the
appropriate antibodv, but it remains to be
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shown whether the method is of value in
management ofpatients.
Eighteen patients with hCG-producing
tumours (12 gestational choriocareinoma and
6 malignant teratoma) have been studied by
RID, using antibodies directed against hCG.
Amongst 13 patients with positive RID were
3 with drug-resistant choriocarcinoma and
opacities in the lung fields on computerized
tomography. It was not clear whether these
opacities were the site of viable tumour or
necrotic tissue. RID was definitely positive
at the sites of the opacities in 2 patients and
suggestive in the third. Deposits of active
tumour were subsequently excised from the
relevant area of the lung in these patients,
and this appears to have contributed to
long-term remission in all 3. By contrast, 3
patients with pulmonary opacities on con-
ventional radiology and negative RID do not
appear to have active hCG-producing tumour,
as judged by serum hCG measurements and
in one case by biopsy.
These preliminary results indicate that
RID may be of value in management of
patients with choriocarcinoma, if it is wished




POTENTIAL USE IN AUTOLOGOUS
MARROW TRANSPLANTATION. J. T.
KEMSHEAD*t, J. PRITCHARDI, J. S. MALPASt
& M. GREAVES*, *Membrane Immunology
Laboratory Imperial Cancer Research Fund,
London WC2, tMed. Oncology Lab., St Barth-
olomew's Hospital, London EC], ,Dept of
Haematology, Hosp. Sick Children, London
Advanced neuroblastoma, particularly when
bone and/or marrow metastases are present
(60 +% of cases) has a poor prognosis des-
pite combined treatment with surgery,
radiotherapy and conventional-dose combina-
tion chemotherapy. In children whose
marrows appear by microscopic assessment
to be free of tumour cells, we have recently
used high-dose (melphalan) chemotherapy
with autologous marrow rescue, to seewhether
remission of disease can be prolonged
(Hedley et al., 1979, Exp. Haematol., 7, 360).
Of 12 patients so treated, 3 remain alive and
well but 9 have relapsed-mostly at meta-
static sites. This pattern of relapse might
reflect either failure to control metastatic
disease even by high-dose melphalan or
re-seeding by residual undetected tumour
cells in the reinfused marrow. To investigate
this latter possibility, monoclonal antibodies
to human neuroblastoma have been pro-
duced. A panel of antibodies has been tested
against human neuroblastoma cell lines and
differential expression of antigens both
quantitative and qualitative has been found
between cultures. For example, the mono-
clonal antibody MI/Nl recognizes an antigen
expressed in about 4x the quantity on
CHP100 cells when compared to CHP212
cells (Kemshead et al., submitted). Similar
heterogeneity in the binding of monoclonal
antibodies is found on analysis of bone
marrow aspirates from children with meta-
static neuroblastoma. The biological signi-
ficance of this antigenic modulation will be
discussed and the possibilities for the diag-
nostic and therapeutic use of these antibodies
in the management of patients with neuro-
blastoma will be assessed.
USE OF A GLUCOCORTICOID-
SENSITIVE HUMAN LYMPHOID CELL
LINE TO STUDY INTERACTIONS
BETWEEN PREDNISOLONE AND CY-
TOSINE ARABINOSIDE IN VITRO.
M. R. NORMAN & R. GLEDHILL, Department
of Chemical Pathology, King's College Hos-
pital Medical School, London, SE5 8RU
The established human cell line CCRF CEM,
which was originally derived from a patient
with acute lymphoblastic leukaemia, was
used to isolate a glucocorticoid-sensitive
clone, C7 (Norman & Tompson, 1977, Cancer
Res., 37, 3785) and we are now using these
cells to simulate the chemotherapy of
leukaemia in vitro. We have examined the
interaction between prednisolone and cyto-
sine arabinoside (Ara-C) according to two
protocols: (i) Awith Ara-C present during the
final 24 h of a 48 h exposure of cells to pred-
nisolone, and (ii) with Ara-C present only
during the 24 h prior to a 48 h treatment with
prednisolone. At a concentration of 10-8M,
Ara-C had no measurable effect on lympho-
blast cloning efficiency in agarose gels, but
nevertheless in protocol (i) it reduced the
number of cells killed by prednisolone
(0.5 to 5 x 10-6M). In protocol (ii) the same
concentration of Ara-C increased cell killing
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by prednisolone (10-6M) at 24, 48 and 72 h.
These results show that the timing of steroid
administration may be crucial when used in
conjunction with other drugs.
TUMOUR OSTEOLYSIS: RESPONSE
TO DIPHOSPHONATES AND PRO-
STAGLANDIN INHIBITORS. A. W.
SAMUEL, C. S. B. GALASKO, S. RUSHTON &
E. LACEY, Department of Orthopaedic Surgery,
University of Manchester, Hope Hospital,
Salford
Previous studies (Galasko & Bennett, 1976,
Nature, 263, 508) have shown that prosta-
glandin-synthesis inhibitor indomethacin can
reduce rabbit VX2 carcinoma prostaglandin
activity, osteoclast proliferation and osteoly-
sis. Twenty-seven human mammary car-
cinomas and 20 VX2 carcinomas were cul-
tured against neonatal mouse calvarias,
tumour osteolvsis being calculated by meas-
uring calcium release. Anti-inflammatory
drugs indomethacin, Ibuprofen and Flurbi-
profen and the diphosphonates, ethane
hydroxy diphosphonate and dichloromethyl-
ene diphosphonate, which affect bone resorp-
tion directly, were added to the culture
medium. Significant reductions in tumour
osteolysis were obtained for all drugs (P<
0.001) and VX2 carcinoma (t test) whereas
the diphosphonates and indomethacin were
the most effective drugs with mammary
carcinoma, (P<0-001). The diphosphonates
would seem to be as effective as the most
effective anti-inflammatory drug in reducing
tumour osteolysis, suggesting these agents be
evaluated as adjuvant therapy in "early"
mammary carcinoma when osteoclastic pro-
liferation would be most marked.
EFFECT OF 4-HYDROXYANISOLE
4HOA ONMELANOMA.D. J.T. WEBSTER,
R. H. WHITEHEAD & L. E. HUGHES, Depart-
ment of Surgery, Welsh National School of
Medicine, Cardiff
It has been suggested that substituted phenols
might be effective cytotoxic agents in malig-
nant melanoma. 4-Hydroxyanisole (4HOA)
is cytotoxic to cultured melanoma cells at
10-4M. Such tissue levels can safely be
obtained in mice, as the required dose is well
below the LD50 (400 mg/kg). We have there-
fore studied its effect on transplanted B16
melanoma in mice, and subsequently on
patients with advanced malignant melanoma.
Male C57 BL mice were inoculated with
5 x 105 B16 melanoma cells, into the right
thigh, on Day 0. They were randomly
allocated to one of 3 groups and were treated
by the appropriate protocol: Group I, 0-1 ml
saline i.p. daily (control group); Group II,
2-5 mg 4HOA in 0-1 ml i.p. daily (prophy-
lactic group); Group III, 0-1 ml saline i.p.
daily until Day 8, then 2-5 mg 4HOA daily
(treatment group). Prophylactic use of
4HOA delayed the appearance of tumours
(7 days vs 9 days, P=0-02 Wilcoxon rank-
sum test) but all animals developed tumours.
At sacrifice on Day 15 there were no signi-
ficant differences in tumour weights: Group I,
2 06 + 0 73 g; Group II, 1-71 +0-64 g; Group
III 1x92 + 0 97 g. Subsequent pilot studies in
patients with advanced malignant melanoma
have been started. Twelve/21 cutaneous
nodules of malignant melanoma directly
injected with 12-5 mg 4HOA underwent
temporary regression. I.v. 4HOA was well
tolerated in 6 patients up to doses of 1-5 g
and total doses of 7-5 g. Nausea was a fre-
quent complaint and in one patient a tran-
sient fall in peripheral leucocytes was seen.
No serious side effects were seen, and one
patient had a briefpartial response. Although
these results are not very encouraging,
further assessment of this agent using
different protocols may be justified.
THE ENHANCEMENT OF EFFECT OF
CHEMOTHERAPEUTIC DRUGS BY
RADIOSENSITISERS: W. M. C. MARTIN
& N. J. MCNALLY, Gray Laboratory of the
Cancer Research Campaign, Mount Vernon
Hospital, Northwood, Middlesex
Cells from s.c. tumours ofthe culture-adapted
sarcoma. WHFIB, were found to exhibit
repair of potentially lethal damage (PLD)
after treatment by cyclophosphamide (CY).
Misonidazole (MISO) given 1 h prior to CY
inhibited this PLD repair and caused poten-
tiation of CY cytotoxicity, which was more
marked at 24 h than 4 h after CY injection.
1 mg/g MISO caused a dose-modifying factor
(DMF) of 2-1 with this system. Comparable
effects were also found using the regrowth-
delay assay. Other 2-nitroimidazole radio-
sensitizers also potentiated the action of CY.
72973ACR AND RSM JOINT MEETING
MISO given 6 h before CY, simultaneously,
or even 2 h after, caused significant potentia-
tion of cytotoxicity, but MISO given 1 h
before CY produced the optimal effect. There
was a linear relationship between sensitizer
dose and the regrowth delay following com-
bined treatment. With melphalan, 1 mg/g
MISO caused a DMF of 2-5. 2 mm WHFIB
lung tumours did not exhibit repair of PLD
after CY and also showed less potentiation of
CY cytotoxicity by MISO than s.c. tumours.
Normal-tissue effects have been encouraging:
the CY-induced LD50/60 was altered by less
than 10b/ by combination with 1 mg/g
MISO; and 1 mg/g MISO caused no signifi-
cant increase in leueopaenia with therapeutic
doses ofCY.
IN VITRO RADIATION SURVIVAL
CURVES FOR SOME HUMAN TUM-
OURS NOT PREVIOUSLY ADAPTED
TO CULTURE. V. D. COURTENAY & J.
MILLS, Radiotherapy Department, Institute of
Cancer Research, Sutton, Surrey
The response to y-radiation was measured in
8 different human tumours, using a replenish-
able soft-agar-colony technique described by
Courtenay & Mills (1978, Br. J. Cancer, 37,
261). The tumours examined were 3 melano-
mas, 3 ovarian carcinomas and 2 pancreatic
adenocareinomas. They were grown as
xenografts in immune-suppressed CBA mice
and maintained in serial passage, with the
exception of one of the ovarian tumours,
M-hich w-as taken directly from the patient in
the form of ascites. Single-cell suspensions
prepared from the tumours were exposed to
y-rays from a 60Co source under oxygenated
conditions.
The shapes of the survival curves were
similar within each tumour category, but
were dissimilar for different categories of
tumour, particularly in the shoulder region.
Average radiation parameters calculated by
linear-regression analysis for the melanomas.
ovarian and pancreatic tumours, respectively,
were Do= 1-4, 0-88 and 1 Gy and Dq=3-0,
2-5 and 0 4 Gy. Ifthese measurements reflect
the radiosensitivity of the original tumour
in the patient, they could explain the poor
respornse to fractionated radiotherapy of
certain types of tumours, particularly mel-
anomas. treated with small dose fractions.
MEASUREMENT OF THE UPTAKE
OF DAUNORUBICIN BY FLOW
MICROFLUORIMETRY. A. T. McGoWN
& B. W. Fox, Paterson Laboratories, Christie
Hospital and Holt Radium Institute, M1an-
chester M120 9BU
Flow microfluorimetry offers a rapid and
sensitive technique for the investigation of
cellular Daunorubicin (DnR) (NSC-82151)
incorporation. The intrinsic fluorescence of
DnR gives a direct measure of the intra-
cellular drug concentration.
The rate and extent of drug incorpora-
tion into P388 murine lymphoma cells in
culture is dependent on several parameters.
The process ofdrug accumulation is tempera-
ture dependent, an increase in uptake accom-
panying a rise in incubation temperature.
Variation of the pH of the culture medium
indicates that the drug is taken up in its
deprotonated form (pKa=825, Dano, 1973,
Biochim. Biophys. Acta, 323, 466). The rate
and extent of uptake is also proportional to
the concentration of drug in the incubation
medium.
The presence ofserum lowers the total drug
incorporation. Albumin, a major componen t
of serum, shows a similar effect. However,
no evidence for DnR-albumin interactions
has been found by optical or fluorimetric
methods.
The metabolic inhibitors 2-deoxyglucose
and azide have no effect on the drug accumu-
lation.
Recent improvements in the sensitivity of
flow microfluorimetry (Keene & Hodgson,
Cytology (in press)) allow us to observe the
cells. However, no pattern is observed in
living cells.
COMPARATIVE KINETIC EVALUA-
TION OF THE METABOLIC N-DE-
METHYLATION OF HEXAMETHYL-
MELAMINE (HMM) AND ITS META-
BOLITES IN VITRO. C. J. BRINDLEY &
A. GESCHER, Cancer Chemotherapy Research
Group, Department of Pharmacy, University
ofAston in Birmingham
Experimental antitumour tests and results
from clinical trials indicate that none of the
N-demethylated metabolites of HMM is more
effective or less toxic than the parent drug.
Yet there is strong evidence that HMM
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itself is not cytotoxic and requires metabolic
activation (A. E. Bateman et al., 1979, Br.
J. Cancer, 40, 81). The N-methyl groups in
the HMM molecule are essential for anti-
neoplastic activity and undergo extensive
metabolic oxidation in vitro and in vivo. We
characterized the enzyme system which
catalyses the N-demethylation of HMM and
its metabolites, to elucidate the relationship
between biotransformation and differences in
cytotoxicities of these agents, and to explain
the pharmacokinetic profiles of HMM meta-
bolites after HMM administration (M. Brog-
gini et al., Cancer Treat. Rep., in press). The
following apparent KM values were calculated
by determining colorimetrically the total
amount of formaldehyde and formaldehyde
precursors produced during the incubation












































The affinity of these compounds for the
mixed-function oxygenases appears to be
related to the number of N-methyl moieties
within the molecules, and the long plasma
half-lives of TetraMM and TriMM after
HMM administration may be associated with




RAT AND MOUSE. C. J. RUTTY, D. R.
NEWELL, J. F. R. MUINDI & K. R. HARRAP,
Department of Biochemical Pharmacology,
Institute of Cancer Research, Sutton, Surrey
Despite marked activity against certain
experimental mouse tumours, and in particu-
lar a number of human tumour xenografts,
phase I clinical studies with pentamethyl-
melamine (PMM) have failed to demonstrate
any complete or partial responses in man
(1980, Proc. Am. Assoc. Cancer Res., 21, 136,
143, 178, 347). A pharmacological rationale
has been sought to explain this apparent
discrepancy. Oxidative N-demethylation of
PMM to lower methylmelamines has been
demonstrated in man, rat and mouse. This
proceeds via N-methylolmelamines, which
are thought to be responsible for the anti-
tumour activity (1980, Chem. Biol. Interact.,
29, 235). PMM and its N-demethylated meta-
bolites were measured in plasma by HPLC,
and N-methylolmelamines by a micro-Nash
technique. In the mouse PMM was meta-
bolized rapidly and extensively to N-methyl-
olmelamines (tj 12 min). However, in the
rat PMM metabolism was significantly slower
(tj=38 min) and the levels of N-methylol-
melamines correspondingly lower. In man
the rate of PMM metabolism was consider-
ably slower (tj=108 min) and N-methylol-
melamines were not detectable. These meta-
bolic differences may explain the sensitivity
of certain mouse tumours, and human
tumours grown in the mouse, and the lack of
clinical response to PMM. The direct admin-
istration of N-methylolmelamines would cir-
cumvent the need for metabolic activation,
and might thereby lead to improved thera-
peutic efficacy.
STRUCTURALLY DIVERSE HEPATO-
CARCINOGENS IN VIVO INDUCE
DRUG RESISTANCE IN RAT
HEPATOCYTES WHEN TESTED IN
VITRO. B. I. CARR, Department of Medical
Oncology, City of Hope National Medical
Center, Duarte, California 91010, U.S.A.
Carcinogen-altered cells have generally been
shown to be more resistant to the toxic
effects of carcinogens than normal cells
(review: Diamond, 1969, Prog. Exp. Tumor
Res., 11, 364) as predicted by Haddow (1938,
Acta Unio Int. Contra Cancer, 3, 342). It
was therefore reasoned that the marked
resistance ofhuman hepatocellular carcinoma
to cytotoxic chemotherapy might also be due
to a carcinogen-induced phenotypic change
in hepatocytes, resulting in an increased
resistance to both carcinogen- and chemo-
therapy-mediated cytotoxicity.
Male F344 rats were fed a basal diet and
given aflatoxin B1 (AFBi) 30 ,tg daily i.p.,
or a basal diet containing either ethionine
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0 25% (w/w), or 3'-methyl-4-dimethylamino-
azobenzene (0.06% (w/w). Rats were sacri-
ficed weekly and their hepatocytes were
placed in primary monolayer culture. Follow-
ing a 3h attachment, hepatocytes were
exposed for 24 h to Adriamycin (1-8 x 10-4M)
cycloheximide (7 x 10-3M) or AFB1 (10-6M).
Resistance was defined as the percentage of
attached cells excluding trypan blue com-
pared to untreated controls. Each of the
3 carcinogens induced > 500o resistance to
AFB1 in the isolated hepatocytes after one
week, and comparable resistance to cyclo-
heximide and Adriamycin after 4 weeks.
Hepatocytes from normal rats did not sur-
vive these concentrations of test drugs (Carr,
1980, Proc. Am. Assoc. Cancer Res., 21, 110).
In vivo, 3 different hepatocarcinogens
induced marked resistance in rat hepatocytes
to the potent carcinogen AFB1, as well as to
the cytotoxic drug Adriamycin, using an in
vitro assay, several months before the appear-
ance of hepatocellular carcinoma. Clinical
drug resistance may be an early carcinogen-
induced phenotype in primary tumours.
INTERACTION OF PLATINUM CO-
ORDINATION COMPLEXES WITH
THE CONSTITUENTS IN CULTURE
MEDIA AND THE RELEVANCE TO
THEIR REACTIONS IN VIVO. M.
LAVERICK & A. H. W. NIAS, Richard Dimbleby
Department of Cancer Research, St Thomas's
Hospital Medical School, London, SE1 and
P. J. Sadler and I. M. Ismail, Chemistry
Dept, Birkbeck College, London, WC1E
Defined culture media have been devised,
which provide optimal conditions for cell
proliferation and a high plating efficiency.
Media suitable for biophysical studies, such
as radiobiology, may contain constituents
which cause artefacts in biochemical studies,
such as cancer chemotherapy. Previous
experiments with the medium Ham's F12
and the platinum II co-ordination complex
cis-PAD showed a marked change in cyto-
toxicity after a small change in the constitu-
ents of the medium (Szumiel & Nias, 1976,
Chem-Biol Interact, 14, 217). The effect of
the complex CHIP (cis-dichloro-bis (iso-
propylamine) trans dihydroxy platinum IV)
on Chinese hamster ovary (CHO) cells has
been found to be markedly influenced by the
culture medium. The cytotoxicity of CHIP
is less when cells are grown and treated in
Ham's F12 medium than in Minimal Essential
Medium (MEM). The biological half life of
CHIP measured in Ham's F12 at 37°C over
1-2 h showed a biphasic decay in cytotoxic
activity, with half-lives of 30 min and 130
min. Over a similar period at 37°C, no change
in cytotoxic effect is seen in MEM or physio-
logical saline. L-cysteine, used at levels
similar to those found in Ham's F12 medium,
can alone reduce cytotoxicity of CHIP.
Specific interactions between CHIP and
L-cysteine have been detected on a similar
time scale by nuclear-magnetic-resonance
spectroscopy and spectrophotometry. The
interaction of this drug with the culture
medium could also mask or alter the potentia-
ting effect with radiation in vitro. The
choice of media for these studies must there-
fore be decided on the basis of the clinical
environment in which cancer cells are expect-
ed to be growing and would be treated.
THE ROLE OF DNA EXCISIONREPAIR
INTHE RECOVERY OFHUMAN CELLS
FROM CISPLATIN TOXICITY. M. F.
PERA* & J. J. ROBERTS, Institute of Cancer
Research, Royal Cancer Hospital, Pollards
Wood Research Station, Chalfont St Giles,
Bucks. HP8 4SP
* Supported by NCI Fellowship F32CA06525-
01.
We evaluated the capacity of human cells to
recover from the cytotoxic effects ofthe anti-
tumour agent cisplatin, and we studied the
relationship between biological recovery and
DNA excision repair. Normal human fibro-
blasts were grown to confluence and treated
with cisplatin. The treated cells were then
plated immediately, or they were held in the
density-inhibited, non-dividing state for
various times after treatment. Cells plated
immediately after a lh exposure to 40 FLM
cisplatin showed a survival, measured by
colony-forming efficiency, that was 0-21-
1-0% of control values. If the cells were held
in a density-inhibited state after treatment,
no DNA synthesis occurred and survival
increased during a 6-day holding period to
levels , 15-40% of controls. During the hold-
ing period, nondividing cells removed plat-
inum residues from their DNA by a first-
order process with a half-life of 2-5 days.
The relationship between the logarithm of
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cell survival and binding ofplatinum to DNA
was determined for cultures plated immedi-
ately after drug treatment, and it was found
to be similar to that observed for cells that
were held in the non-dividing state and
allowed to perform DNA repair prior to
plating and entry into the proliferative cycle.
DNA-DNA interstrand crosslinks, measured
by determination of the renaturable fraction
of DNA in cell lysates, appeared to be re-
moved at a rate comparable to that of
overall adduct removal. These results show
that human cells can recover from the
cytotoxic effects of cisplatin, that this bio-
logical recovery is related to DNA excision
repair and interstrand crosslink removal, and
that the determinant of cytotoxicity is the
extent of drug-DNA interaction at the time
cells undergo DNA synthesis and division.
ACYLATED DINUCLEOSIDE PHOS-
PHATE DERIVATIVES AS AGENTS
TO OVERCOME RESISTANCE TO
PURINE ANTIMETABOLITES. D. M.
TIDD, I. GIBSON & P. D. G. DEAN,* Universi-
ties ofEast Anglia and *Liverpool
Montgomery et al. (1963, Nature, 199, 769)
reported that a dinucleoside mono-phosphate
derivative of 6-mercaptopurine, bi.s(thio-
inosine)-5',5"'-phosphate, was capable of
inhibiting the growth of 6-mercaptopurine-
resistant H.Ep 2 cells in concentrations at
which 6-mercaptopurine itself was without
effect. This result was not repeated in other
cell systems, nor did other antimetabolite
dinucleoside monophosphates show any
advantage over the parent drugs in terms of
their effects on resistant cell sublines. We
have synthesized pl, P2-bis(6-thioinosine-5')
pyrophosphate and have found that this
compound is roughly equivalent to 6-thio-
inosine in its activity against thiopurine-
sensitive and insensitive L1210 cultures.
Apparently the derivative was cleaved extra-
cellularly, initially to 6-thioinosine and its
diphosphate. In contrast, pl, P2-bis (2',3'-0-
dibutyryl-6-thioinosine-5') pyrophosphate
was less active than 6-thioinosine against
L1210 cells. However, on a molar basis, this
acylated compound was -V85-fold more active
than 6-thioinosine against the thiopurine-
insensitive subline. Similarly, bis(N2-butyryl-
6-thioguanosine)-5',5"'-monophosphate was
less effective than 6-thioguanosine against
thiopurine-sensitive L1210 cells, but 64-fold
50
more active than 6-thioguanosine against the
thiopurine-insensitive cells. Theseresults sug-
gest that the intact acylated compounds were
taken up by cells in sufficient quantity to
generateinhibitoryconcentrationsofactivated
drug nucleotide metabolites by intracellular
cleavage.
INTERACTION OF VP 16-213 WITH
DNA REPAIR ANTAGONISTS. A. M.
ARNOLD & J. M. A. WHITEHOUSE, CRC
Medical Oncology Unit, University of South-
ampton
The podophyllotoxin derivative VP 16-213
can apparently cause single-stranded breaks
in DNA, capable of repair. Several com-
pounds are known to be powerful inhibitors
of DNA repair, so it was of interest to study
the interactions of VP 16-213 with chloro-
quine and caffeine. Female DBA mice
weighing 20 g were inoculated s.c. with 105
TLX lymphoma cells. Three days after
inoculation the animals were treated with
VP 16-213, together with either chloroquine
(20-40 mg/kg) by i.p. injection or caffeine
(0-125-1%) added to the drinking water. By
way of a control, vincristine, a drug not
thought to damage DNA, was also tested
with chloroquine. Results were expressed as
increased lifespan (ILS) over untreated
controls. VP 16-213 alone (6.25 mg/kg and
12.5 mg/kg) produced an ILS of 9% and 30%
respectively. VP 16-213 in the same doses but
together with 40 mg/kg chloroquine produced
ILS of 78% and 76% respectively (P=0 05).
By contrast chloroquine did not enhance the
effect of vincristine. One per cent caffeine
added to drinking water of animals given
VP 16-213 produced a significant but less
marked ILS. These preliminary observations
provide further evidence that the mode of
action ofVP 16-213 may be due to the forma-
tion of single-stranded breaks in DNA,
though it is possible that other mechanisms
may be responsible for the apparent
synergism.
ALKALINE ELUTION STUDIES WITH
BUSULPHAN AND RELATED DIAL-
KANESULPHONATES. P. BEDFORD &
& B. W. Fox, Paterson Laboratories, Christie
Hospital and Holt Radium Institute, Man-
chester M20 9BX
The DNA-DNA and DNA-protein cross-
linking produced by two members of the
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anti-tumour dialkane suiphonic acid esters of
general structure:
CH3SO20(CH2)nOSO2CH3
have been studied, using the technique of
alkaline elution (Kohn et al., 1976, Bio-
chemistry, 15, 4629). The two agents, methyl-
ene dimethanesulphonate (MDMS, n= 1) and
1,4-dimethylsulphonyl-oxybutane (busul-
phan, n=4) have been comparedinthis study.
Both agents were found to produce DNA-
DNA interstrand crosslinks in cells derived
from the transplantable Yoshida rodent
sarcoma. In addition, a substantial number
of DNA-protein crosslinks and a small
number ofsingle-strand breaks were observed
after MDMS treatment. The DNA-protein
component of crosslinking was entirely
attributed to the formaldehyde produced on
hydrolysis of the drug. The approximate
relative occurrence of the observed lesions as
a percentage of total damage after MDMS
was calculated as 26%, 64% and 10%
respectively for DNA-DNA cross-links, DNA-
protein cross-links and single-strand breaks.
At doses producing 50% cell death in the
cross-sensitive YS line, MDMS was found to
induce 0-103 cross-links/109 dalton compared
with 0-151 cross-links/109 dalton after an
equitoxic dose of busulphan. Initial temporal
studies with each agent, using a cell line
resistant to MDMS (YR8) and resistant to
busulphan (YBusR) compared with the
wild-type YS line, suggested that a saturation
ofexcision repair ofthe cross-links could occur
at high doses of each agent in the sensitive
line, whereas this was not the case at equiv-
alent doses in the resistant lines.
THE COMPARISON OF THREE
ASSAYS FOR THE DETERMINATION
OF IN VITRO CHEMOSENSITIVITY
USING HUMAN CELL LINES. A. P.
WILSON, C. E. NEWMAN, C. H. J. FORD & A.
HOWELL, Clinical Oncology Unit, University
of Birmingham, Queen Elizabeth Hospital,
Birmingham
The chemosensitivities of 3 human cell
lines (T13; transformed fibroblasts: MCF-7;
breast ca: Calu 6; lung ca) to Adriamycin
(ADM), Bleomycin (BLM), cis-platinum (CIS),
cyclophosphamide - phosphoramide mustard
(CYM), 5-fluorouracil (FU) and cytosine
arabinoside (CYT) have been determined,
using a biochemical assay (Kauffman et al.,
1978, Strahlentherapie, 154, 277) a clonogenic
assay (Salmon et al., 1978, N. Engl. J. Med.,
298, 1321) and a monolayer assay (Wilson,
1978, Clin. Sci. Mol. Med., 55, 16P). The end
points of the assays were depressions of
nucleotide incorporation, colony formation
and leucine incorporation respectively. All
drugs were tested at 10-2,10-3 and 10-4 mg/
ml. Cell lines were classified as sensitive
(>60% inhibition), resistant (<40% inhibi-
tion) or intermediate (40-60% inhibition).
With ADM, all 3 assays showed good
correlation with sensitivity and resistance,
but for the other drugs the biochemical test
was the least sensitive of the assays and
correlated only for resistance. Calu 6 and
MCF-7 were resistant to CYM in all assays;
T13 was sensitive in the monolayer assay
only. The monolayer and clonogenic systems
correlated well at 10-2 and 10-4 mg/ml, but
there was disparity at 10-3 mg/ml. Reduc-
tion of drug exposure time in the mono-
layer assay from 48 h to 3 h gave absolute
correlation between thetwo assays.
These comparisons were performed as a
preliminary to comparing results using differ-
ent assays on primary human tumours for
the purpose of predictive chemosensitivity
testing for the individual. The results
indicate that the biochemical system is
suitable for testing the sensitivity of cells to
ADM, and that the clonogenic and mono-
layer assays give similar results, particularly
if the drug-exposure time of the monolayer
assay is reduced.
EVALUATION OF THE IN VITRO
RESPONSE OF HUMAN GLIOMAS TO
CHEMOTHERAPEUTIC AGENTS AND
ITS CORRELATION WITH CLINICAL
RESPONSE. J. L. DARLING & D. G. T.
THOMAS, Department of Neurological Surgery,
Institute of Neurology, London, WC1N 3BG
It is well recognized that histopathologically
similar malignant gliomas do not respond
uniformly to single anti-neoplastic agents.
Recent experimental data suggests that this
may be due to a cellular heterogeneity in
response to chemotherapeutic agents. Using
a technique based on scintillation auto-
fluorescence, we have measured the response
of 36 malignant gliomas in vitro. Each
tumour was transferred into monolayer
culture and tested separately against a panel
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of 3 chemotherapeutic agents: vincristine,
CCNU and procarbazine. Response, as
measured by inhibition of protein synthesis,
was determined at a range ofdrug concentra-
tions, following both short-term recovery
(4-24 h) and long-term recovery (4-12 days).
Among the tumours tested, a 1-2-6*7 log
variation in response was noted for each of
the drugs studied.
It was possible to correlate clinical data
with the in vitro data in 6 patients. Of 3
patients that clinicallyresponded, 2responded
in vitro to all 3 drugs and one responded to
2 of the 3 drugs. Of 3 patients who failed to
respond clinically, only one had a significant
responses in vitro to a drug.
These data demonstrate a wide variation
in response in vitro among histologically
similar tumours to single chemotherapeutic
agents. The true significance of this is not
known, but in preliminary analysis a close
correlation is noted between in vitro response
and clinical response.
EVALUATION OF THE DRUG SENSI-
TIVITIES OF HUMAN NEUROBLAS-
TOMA CELLS IN VITRO. B. T. HILL &
R. D. H. WHELAN, Laboratory of Cellular
Chemotherapy, Imperial Cancer Research Fund
Laboratories, London, WC2 3PX
The dismal prognosis for the majority of
children with neuroblastoma highlights the
need for more effective therapies. One
approach is to screen experimentally for
drugs active in this disease. The patterns of
survival of human neuroblastoma (CHP100)
cells were established following a 24 h in
vitro exposure to a range by colony formation
in agar. The dose-response curves were of
two types, exponential-plateau or exponen-
tial. The former category included: hydroxy-
urea, methotrexate, ICRF 159, vincristine,
vindesine, VM-26 and VP-16-213. Exponen-
tial curves were seen with actinomycin D,
adriamycin, bleomycin, cis-platinum, dibro-
modulcitol, 5-fluorouracil, m-AMSA, mel-
phalan and peptichemio. A comparison was
attempted between those drug concentrations
required to reduce survival by 70% under
these conditions, with peak plasma levels
achievable in man. The results obtained,
after many and varied assumptions, allowed
a division of the drugs tested into 3 groups:
(i) most effective agents-m-AMSA, VM-26
and adriamycin, (ii) agents with some
activity-vincristine, vindesine, VP-16-213,
cis-platinum, melphalan and peptichemio,
although only for higher doses of the latter 3
drugs, (iii) agents with little, ifany, activity-
actinomycin D, bleomycin, dibromodulcitol,
5-fluorouracil, hydroxyurea and ICRF 159.
Clinical data suggest value in treating neuro-
blastoma with VM-26 and Adriamycin (in
our Group (i)) and with vincristine, mel-
phalan (high dose), peptichemio and cis-
platinum (in our Group (ii)). No activity
has been reported for actinomycin D or
bleomycin (in our Group (iii)). Our experi-
mental results suggest that clinical evalua-
tion of m-AMSA and VP-16-213 might be
profitable.
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